Clinical and experimental aspects of sacral nerve neuromodulation in lower urinary tract dysfunction by Weil, E.H.J.
  
 
Clinical and experimental aspects of sacral nerve
neuromodulation in lower urinary tract dysfunction
Citation for published version (APA):
Weil, E. H. J. (2000). Clinical and experimental aspects of sacral nerve neuromodulation in lower urinary
tract dysfunction. Maastricht: Universiteit Maastricht.
Document status and date:
Published: 01/01/2000
Document Version:
Publisher's PDF, also known as Version of record
Please check the document version of this publication:
• A submitted manuscript is the version of the article upon submission and before peer-review. There can
be important differences between the submitted version and the official published version of record.
People interested in the research are advised to contact the author for the final version of the publication,
or visit the DOI to the publisher's website.
• The final author version and the galley proof are versions of the publication after peer review.
• The final published version features the final layout of the paper including the volume, issue and page
numbers.
Link to publication
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these
rights.
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal.
If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above,
please follow below link for the End User Agreement:
www.umlib.nl/taverne-license
Take down policy
If you believe that this document breaches copyright please contact us at:
repository@maastrichtuniversity.nl
providing details and we will investigate your claim.
Download date: 04 Dec. 2019
Bij de voorpagina
De cirkcl
in gouden oinhcl/ing
omval hfl weten
gt'opend om if gcven
aan hot vloricnde lilauw
water en «dem
en in de letter«
op griJN tilaan
hft root I van cle licldc
./ft» C7u7<vf
Opgcdragcn aan alien dio mii mot wijsheid. inzicht en liefde inspireren
CLINICAL AND EXPERIMENTAL ASPECTS
OF SACRAL NERVE NEUROMODULATION
IN LOWER URINARY TRACT DYSFUNCTION
PROEFSCHRIFT
ter verkrijging van de graad van doctor aan de Universiteit Maastricht,
op gezag van de Rector MagniPicus, Prof. dr. A.C. Nieuwenhuijzen Krusemun
volgens het besluit van het College van Decunen,
in het openbaar te verdedigen op donderdag 30 november 2000 om 12.00 uur door
ERNEST HENK JOHAN WEIL
Promotor: > /
Prof. dr. Ph.K.v. Van Kerrebroeck " ^ ' i X .'! •' ] ^ / J / . j f ;/r J f ' j
Beoordellngscommissie: / ^ i / > f j / ^ f ( )
'Vol. di. J . |roo»i. (voorzittcr)
»W. (lr. C.G.M.I.
H[
IW.clr. H.A..I. Struijkcr Uoudicr
l'rof.dr. N..J.J. Wellen.
CONTENTS
Chapter 1 General introduction and outline of the thesis. 7
Chapter 2 Anatomy and neurophysiology of the lower urinary tract, 11
Chapter 3 Pathophysiology of lower urinary tract dysfunction. 23
Chapter 4 History of the development of neurostimulntion. 37
Chapter 5 Neuromodulation of sacral nerves for incontinence and
voiding dysfunctions. /4 /<•</.<</////y.<///<>y. ÄI
Chapter 6 Improving neuromodulation technique for refractory voiding dysfunctional
Two-stage implant. ,1 /<•<•/&///<*//.<///,ty. 61
Chapter 7 Clinical results of sacral neuromodulation for chronic voiding dysfunction using
unilateral sacral foramen electrodes. /I Av»<7-/r/7// /l>///»<t'-///> .<///rty. 73
Chapter 8 Sacral root neuromodulation in the treatment of refractory urinary urge incontinence.
/. 89
Chapter 9 Novel test lead designs for sacral nerve stimulation.
Improved passive fixation. /I« <I/I//M<I/,»///<ty. 111
Chapter 10 Buttock placement of the implantable pulse generator
a new technique for sacral nerve stimulation. 125
Chapter 11 Summary and conclusions. 137
Chapter 12 Samenvatting and conclusies. 143

General introduction and outline of the thesis
Chapter 1
GENERAL INTRODUCTION AND OUTLINE OF THE THESIS
General introduction Functional problems of the lower urinary tract are a significant problem. The
total number ol patient» with urinary incontinence is estimated at 700.000 in a population of 16 mil-
lion (1-3). A third ol them show symptoms ol bladder overactivity. A similar number of patients are
Buffering from «everc urgency frequency complaints (3,4). Probably comparable numbers of patients
are suffering Irom severe voiding symptoms based on functional abnormalities (3). The symptoms in
I lie HI- patients have a negative influence on their quality of life and the majority of patients will request
treatment (.'>,(>,<)). Conservative treatment modalities such as bladder retraining and pharmacological
manipulation will be successful in about (>0% of these patients (7,8,10). However, 40% of patients
ithow significant persistent symptoms. Surgical treatments have been offered but with a high morbi-
dity and poor long-term results (3.4). The costs of conservative treatment are increasing dramatically
( I I ) . Kurt IHT information on tin- inurophysiological control of lower urinary tract behaviour and elec-
tronic developments have permitted the development of new treatment modalities making use of elec-
trical stimulation. One form of such treatment is called 'Sacral Nerve Neuromodulation'. Using this
technique, an electrical current is applied to a sacral nerve in order to rebalance or modulate the
reflexes involved in lower urinary tract control.
Aim of the thesis The exact place of sacral nerve stimulation for urological patients is still a matter
ol discussion. Since there is a broad variation in the clinical picture of patients with lower urinary tract
dysfunction, it is dillicult to establish a clear picture ol the efficacy ol this treatment modality in spe-
cific groups ol patients. Also medium and long-term follow-up data are lacking.
This study discusses current knowledge of the pathophysiology of lower urinary tract dysfunction in
patients with functional disorders in relation to the application and the development of sacral nerve
neuromodulation as an accepted treatment.
The anatomy and pathophysiology/ of lower urinary tract function are described in order to explain
the possible working mechanisms of sacral nerve neuromodulation. The complex nerve control of
lower urinary tract function is discussed in detail. The etiology of lower urinary tract dysfunction is
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discussed with reference to reflex control. In several clinical studies the role of sacral nerve neuro-
modulation in specific groups of patients has been studied. Technical improvements are described in
order to make the technique of implantation and selection of patients based on percutaneous nerve
evaluation more reliable and successful.
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Chapter 2
ANATOMY AND NEUROPHYSIOLOGY OF THE LOWER URINARY TRACT
The lower urinary tract consists of the bladder, the lower one third of the ureter and the ureterovesi-
cal junction, the prostate gland and the urethra, together with its smooth and striated muscles. The
bladder is a hollow musculomembranous organ lined with several layers, usually six, of transitional
epithelium. Underneath these layers, the lamina propria forms a thick layer of connective tissue, allo-
wing considerable stretching of the bladder. In the trigone, no connective tissue is situated between
the muscles and the epithelium. Therefore, this part of the bladder does not wrinkle when the bladder
is empty. The lamina propria contain» a rich supply of blood vessels, nourishing the bladder.
A smooth muscle layer is situated close to the lamina propria. This layer actually consists of three lay-
ers, each of them traversing in a different direction. The inner layer is longitudinal and criss-cross, the
middle circular and the outer is longitudinal ( I ) . These direction« ;ixivm^t.^r»»ww<riii'Tirliic'oiauAier-
neck. In the upper part of the bladder, the direction of these muscle fibers is not clearly identifiable.
However, the structure of this detrusor muscle is ideal for emptying the bladder. In the male bladder,
the middle circular layer continues into the urethra, almost as far as the verumontanum. This forms
tin- internal sphincter, richly innervated by sympathetic nerves. In the female bladder, the muscle layer
has a longitudinal direction; therefore, women have a less efficient internal sphincter.
The main function of the bladder is to store urine continually produced by the kidneys and evacuation of
the urine whenever this is appropriate. This means that sufficient bladder capacity is needed, which allows
sufficient time between voids. Alter voiding, the bladder should contain none or a minimal amount of urine.
Dining filling of the bladder, volume increases, simultaneously increasing the bladder outlet resistance.
IJasicallv, as long as urethral pressure minus detrusor pressure is more than zero, no urine will be lost. The
dual function of the bladder and urethra is organized at different levels of the central nervous system. The
discussion on the neuronal organization of micturition and the storage of urine is still going on.
Micturition is a complex function that involves co-ordinated interactions between the smooth muscle
of the bladder and the urethra. The peripheral nervous system serves to co-ordinate these actions.
while ihe central nervous system serves to inhibit or initiate and thereby modulate these actions.
In the mature animal, the ultimate control of micturition resides in the central nervous system and is under
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control of the cortex. With maturity, cortical input is mandatory to determine the optimal social setting
for micturition. The cortical input then serves to remove any inhibition of the micturition centre, which in
turn removes any descending inhibiting signals. It is the supraspinal structures that allow the micturition
to proceed. Upon completion of micturition, the spinal pathways return to the inhibiting mode. -
Bladder innervation The autonomic nervous system, which consists of the parasympnlhetic and
sympathetic nerves, and the somatic nervous system are both involved in controlling the lower urina-
ry tract.
Several authors have described several pathways for bladder innervation. Most ol these pathways were
discovered in animal studies. For that reason, a complete model ol the human innervation ol the lower
urinary tract is ditVicult to provide (2). Consensus has not yet been established. In the past, it was thought
that bladder function fully relies on reflex mechanisms at the sacral level. Recent resrai vh by I lolslege
and Blok has emphasized the important role of supraspinal pathways in the lower urinary tract (3).
Peripheral pathways Both the autonomic and the somatic nervous systems are involved in ihr control
of the lower urinary tract. The somatic nervous system controls the striated musculature ol the pelvic lloor
and the urethra (4). The pelvic floor is innervated by somatic fibers carried in the pudendal nerve.
The autonomic innervation of the lower urinary tract has a parasvmpathetic and a sympathetic ner-
vous svstem. The afferent parasvmpathetic pathways run from the ventral segments ol S!2 to S4 in the
spinal cord to a relay station in the pelvic plexus. The pelvic nerve contains predominantly parasym-
pathetic nerve fibers. Synapses occur in the ganglia of the pelvic plexus and in the juxta and intra-
mural ganglia of the bladder. The sympathetic nervous system uses two different pathways lo link the
target organs to the vesicomotoneurons inside the thoraco-lumbar spinal cord. The fiber« leave I he
thoraco-lumbar spinal cord synapse in the sympathetic chain on the paravertebral ganglia or traverse
it. Part of the nerve fibers then run to the superior hypogastric plexus. From here nerve fibers run via
the left and right hypogastric plexus to the juxta and intramural ganglia to innervate the bladder and
urethra. The other nerve fibers descend via the sympathetic chain and synapse in the pelvic plexus.
Ascending pathways from the bladder Autonomie afferent« from the bladder start in the
mechanoreceptors in the bladder wall. Afferent parasvmpathetic pathways travel Irom these receptors
13
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in the bladder to the sacral spinal cord via the pelvic nerve. Afferent sympathetic pathways also tra-
vel from these receptors in the bladder wall, which are conveyed by the pelvic nerve. These neurons
enter the spinal cord. Somatic affercnts are conveyed by the pelvic nerve and project to the Onuf's
nucleus in the spinal cord (2,5-12). The pelvic floor muscles and the striated musculature of the
urc I lira I »phincter arc conveyed by the pudendal nerve. These neurons synapse in the dorsal horn of
the spinal cord. It is also suggested that these neurons project to Onuf's nucleus, indicating a myoto-
nic reflex arc (2).
Afferent« travelling via the pelvic nerve to the sacral spinal cord consist of small mvelinated (A6) and
unmyclinatcd (C) fibers (13). The myelinated AÖ afferents are connected to the mechanoreceptors
(volume and tension receptors) (14,15) and respond to stretching distension of the bladder. The C-fiber
afferent» do not respond to distension but they are activated by noxious stimuli, like irritation or
'inflammation. Therelore, they cause a painful sensation. In animal testing, rellex micturition is initiated
by bladder Tilling. The Aö-liber aflerents detect bladder distension. C-fiber afferents are not involved in
normal voiding mechanisms but can modulate voiding reflexes and induce hyperactivity in response to
bladder pain (b). Mechanoreceptor aflerents from the bladder and urethra have also been identified in
sympathetic nerves passing to the lumbar cord. These afferent neurons consist of myelinated and unmv-
elinaled axons, which respond to stimulus modalities similar to those triggering afferents in the pelvic
nerve (16). The function of the sympathetic nerve arterents is still obscure. Clinical observations suggest
that they forward nociceptive information. Afferents from the urethra, travelling in the pudendal nerve,
induce the sensations of pain, temperature and passage of urine. These aflerents and the pudendal nerve
afferents from the striated sphincter muscle have a modulatory influence on micturition.
Spinal Center This functions as a relay center for afferent and efferent pathways. It does not contain
grey matter nuclei (17). The sympathetic neurons are located in the tractus intermediolateralis of the
spinal cord T l 1-L2 (1,18). The parasympathetic preganglionic neurons are located in the S2-S4 seg-
ments of the spinal cord (19). Somatic efferents are located in the anterior horn of S2-S4 in an area
called Onuf's nucleus (also known as the pudendal nucleus or sphincter motor nucleus) (20).
The Cerebellum The cerebellum serves to modulate motoractivity that is initiated in other parts of
the central nervous system. It receives sensory afferents from the bladder and pelvic floor muscles. Its
H
Chapter 2 ^ t *-
efferent role is to maintain tone and co-ordination in the striated muscles of the pelvic Hour and peri-
urethra! striated muscle, and it has an influence on co-ordinating relaxation of the pelvic floor with
detrusor contraction. It is also suggested that it is responsible tor suppression of spontaneous detrus-
or contractions (9,21-23). In addition, cerebellar ataxia can cause hyperretlexia of the bladder (2*4).
Basal ganglia The basal ganglia are nuclei located below the cortex and adjacent to the thalamus.
There is evidence that these structures have an inhibitory influence on the pontine micturition center
in that spontaneous detrusor reflex contractions are suppressed (26,2o). The clinical correlate is seen
in patients with Parkinson's disease who have lost their dopaminergic neurons within the subslantia
nigra. and who have hyperactive detrusors. Stimulation of certain zones in the striale nuclei appears
to suppress the micturition reflex. Destruction of these zones leads to hyperrellexia (27).
The thalamus and hypothalamus The thalamus is a collection of nuclei that together relay sensory
information upward to the cerebral cortex (28). It relays sensory afferent» from the sphincter lo the
cortex (29). The hypothalamus consists of major groups of nuclei whose known cllects include main-
taining body temperature and fluid balance through neuro-endocrine mechanisms. It seems that the
thalamus and hypothalamus are involved in the control of micturition and defecation through the
autonomic nervous system (30,31).
The limbic system The limbic system comprises areas located primarily in tin- temporal lobe.
Depending on the stimulated zones, bladder activity may be facilitated or inhibited. As mentioned
before, the bladder and its sphincter have two main functions: storage of urine and voiding or mictu-
rition. In the storage phase, the external urethral sphincter is tonically contracted, while the detrusor,
the muscle of the bladder, is relaxed. During the micturition phase, the opposite take» place. The de-
trusor contracts and the external urethral sphincter relaxes (32). The synergy between detrusor and
external urethral sphincter is under brain stem control ( I I ) (33). The brain stem neurons are located
in a medial and a lateral cell group in the dorsolateral pons (34). The medial cell group specifically
projects via long-descending pathways to the sacral intermedial cell group and to the intermediolater-
al cell column containing autonomic motor neurons to the detrusor muscle of the bladder. The medial
cell group in the dorsolateral pons is called the M-region (33), or Barrington's nucleus (1925), or pon-
tine micturition center. The lateral cell group is called the L-region (33) and sends fibers throughout
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the length ol the spinal cord to the nucleus of'Onuf in the SI-SI V spinal segments. OnuPs nucleus con-
tains motor neurons innervating the pelvic iloor including the external urethral sphincter as men-
tioned in the sacral spine anatomy. Klectrical stimulation in the M-region produces an immediate and
•harp decrease in the urethral pressure and pelvic floor KMC. followed after 2 seconds by a steep rise
in inlra-vesical pressure as a result of contraction of the bladder (33).
Bilateral lesion* of the M-rcgion result in long-term retention of urine (35). Electrical stimulation in the
L-region result» in strong excitation of the pelvic Iloor musculature and an increase in the urethral pres-
sure, because ol strong contraction of the external urethral sphincter (33). Bilateral lesions of the L-
region produce urine incontinence (36). The M-region may be regarded as the micturition control cen-
ter and the I/-region as the control centre for storage of urine. The M-region is stimulated by the PAG
(Peri Aqucductal (»ray). Information concerning the degree of bladder filling enters the I urn bo-sacra I
cord via aflerents in the pelvic nerves. These afferents terminate on sensory neurons in the dorso-
luteral pari ol the caudal lumbar and sacral spinal cord. These sensory neurons receiving bladder fil-
ling information project to the lateral and dorsal parts of the periaquaductal grey. If the bladder is suf-
ficiently filled, the PA(1 turns on the 'switch' to start micturition via its projection to the M-region.
Finally, the M-region starts micturition by inhibiting the urethral sphincter and activating the bladder
via descending pathways to the sacral parasympathetic neurons (36). It is not yet known in which
brain structure voluntary micturition is initiated. Holstege presents the existence of 3 motor systems
(37,38). The first system is formed by the pre-motor interneuronal projections of the motor neurons.
These neurons receive direct or indirect afferent information from the periphery via peripheral af-
I'erent nerves and from the second and/or third motor systems. They are of paramount importance for
determining the final output of the motor neurons. It is not always true that these interneurons are
located close to the target motor neurons. Holstege classifies the micturition-related inter-neurons in
the dorsolateral pons .is part ol this system. They are of importance for micturition, because they
determine whether bladder and bladder-sphincter function synergistically. via their long-descending
pathways.
The question arises why those neurons are located so far from their target motorneurons. In that
respect, it is important to realize that micturition is correlated with the emotional state of the indivi-
dual. Therefore, the micturition interneurons need to receive afferent information from the limbic sys-
tem, which is available in the dorsolateral pons, but not in the sacral cord. The interneurons involved
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in blood pressure control and projecting to the sympathetic motor neurons in the intei-mediolatei al cell
column of the thoraco-lumbar cord are located in the ventrolateral medulla. Their alVerent informa-
tion enters the central nervous system via the brainstem (vagal nerve), while alVerent information from
the hmbic system that plays an extremely important role in determining the level of the blood pressure
is also available. The second motor system consists of thick fibers that can be detected using the lesion
degeneration technique. The fibers of this system terminate only to a limited i v t .n i directly on motor
neurons, but for the most part on the inter neurons of the first motor system. The second system is the
so-called somatic component of the motor system. It consists of a medial and a lateral component. The
medial motor column controls eve and neck movements and axial and proximal body movements. The
lateral motor column innervates the distal body musculature for independent movements of the extre-
mities. The third motor system was discovered only recently using modern tracing techniques. It con-
sists of thin fibers and therefore could not be demonstrated using earlier lesion-degeneration techni-
ques. The third system seems to be the limbic component of the motor system. 'This also consists of a
lateral and medial part. The medial component originates in the medial portions of the hypothalaimis
and in the mesencephalon and terminates in the ventral pan of the caudal ponlinc and medial aeg-
mental field.
The lateral component originates laterally in the limbic system and in the lateral hypothalamus. These
structures project to the lateral segmental field of the caudal pons and medulla, but not to the soma-
tic motor neurons in this area. Within in the PAG (Peri-Aqueductal Grey), the center that can trigger
the M-region and the lateral adjacent tegmentum, some specific groups of neurons are found. These
neurons are probably related to specific functions, such as vocalisation, head movements involved in
emotional behaviour or blood pressure control. The emotional brain has a great impact on the sensory
as well as on the motor system. In both systems, it sets the gain or level of functioning of the neurons.
The emotional state of the individual determines this level. For example, it is well known lli.il many
forms of stress such as aggression, fear and sexual arousal induce analgesia, while at the same time the
motor neuron is set at a high' level and motor neurons can easily be excited by the second motor sys-
tem. In this concept, the brainstem structures, which project diffusely to all parts of the spinal cord,
can be considered as tools for the limbic system controlling spinal cord activity. The lateral component
of the third motor system projects to the caudal brainstem lateral segmental field (not far from the dor-
solateral area where the M-region is located), which contains first motor system interneurons invol-
17
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ved in specific lunctions such as respiration, vomiting, swallowing, chewing and licking. These activi-
ties are displayed at the beginning of fight or defense response and can be easMy elicited by stimula-
tion of lateral parts of the limbic system. Therefore, it seems that the lateral component of the third
motor system is involved in more specific activities, related to emotional behaviour. Although the exis-
tence of an 'emotional motor center' never has been demonstrated in human beings, it could be quite
possible dial emotional behaviour in humans can have an acute and long-term influence on the con-
Irol <>i urine storage and micturition. There is clinical evidence that in circumstances of stress, like
moment« of fight and flight, micturition or detrusor contraction can be provoked. From clinical expe-
rience, it is well known that psychological and psychiatric problems in human beings such as for example
•treM, depression and sexual abuse have a direct effect on micturition behaviour and pelvic floor. This can
lend to symptom!« like urgency, frequency, urge incontinence and even retention.
Voiding mechanisms Voiding starts when tension receptors in the bladder wail reach a threshold
tension, due to bladder filling (39). Afferents start firing bursts via the pelvic nerve, entering the spi-
nal cord at L-4-S2 and ascend in the lateral spinothalamic tract (36). These afferents activate a spin-
ulbulhospinal reflex that passes through the pons (5,40). These sensory neurons in turn project to the
lateral and dorsal parts of the peri-aquaductal grey (PAG). The PAG then switches from urine stora-
ge to urine release, starting micturition via the M-region. The M-region also receives information from
ihe .mgulalc gyms, medial preoptic region of the hypothalamus, bed nucleus of stria terminalis and
amygdala; these structures are concerned with emotional and homeostatic activities (3,36). If the PAG
lias turned the 'switch' to start voiding, the M-region will increasingly excite the sacral parasympa-
thetic motor neurons, causing (»ladder contraction. Simultaneously, the L-region is inhibited by the M-
region, causing relaxation ot the intrinsic external urinary sphincter and pelvic floor via Onufs
nucleus and the pelvic nerve (3).
In addition, the inhibitory effect of the vesieosympathetic reflex is eliminated by the M-region s acti-
vity. Uecause the M-region has connections to the intermediomedial cell group, this is a part of this
vesieosympathetic reflex arc. The inhibition will end detrusor inhibition and cause bladderneck ope-
ning (2).
IK
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Storage mechanisms To achieve continence, the urethra should be closed at the level of the sphinc-
ter. This means that the urethral sphincter pathways should be stimulated, especially during a rise in
abdominal pressure as for example coughing. In addition, the micturition reflex (spinobulbospinal)
should be inhibited. During bladder tilling, the vesicosympathetic reflex is activated via alVerents in
the pelvic nerve (41). The sympathetic activity of these nerves induces a negative feedback mecha-
nism, which inhibits the bladder and allows further bladder stretching. The efferent sympathetic
action: closure of the vesical neck and proximal urethra due to direct stimulation of 8-adrenorecep-
tors, and stimulation of 8-adrenoreceptors inside the bladder wall, inhibiting the bladder (11,12,42-
44). The inhibitory input of the hypogastric nerve is stopped prior to voiding (41). Due to an active
L-region, Onuf's nucleus is stimulated; urethral closure is supported by contraction of the pelvic floor
and intrinsic external urethral sphincter (5,42). Presumably, the M-region is inhibited by the uctivity
of the L-region. A rise in intravesical pressure of a full bladder causes an increased activity of the stria-
ted musculature in the pelvic floor. This reflex is called the guarding reflex (45).
19
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PATHOPHYSIOLOGY OF LOWER URINARY TRACT DYSFUNCTION
INTRODUCTION
Micturition conaisls of a filling phase and a voiding phase. During the filling phase, urine is stored
and during the voiding phase bladder content is eliminated from the body at socially convenient times.
Thus, the pathophyaiology ot lower urinary tract (LUT) can be divided into storage and voiding dis-
order«. The neural regulation of the LUT is complex and still the object of research. An intact neural
axis from the cerebral cortex, through brainslcm, spinal cord, sacral micturition center and peripher-
al nerves innervating the bladder is crucial lor normal bladder functions. Many different neurotrans-
mitler palliway» are involved, modulating proper voluntary control over the reciprocal relationship
between the storage function of the bladder and the outlet sphincters of the urethra. When voluntary
control is lost or disrupted due to neurological disease or damage, the aberrant reflexes can take over,
resulling in incontinence, abnormal frequency of urination or urinary retention.
STORAGE DISORDERS Bladder overactivity
The most common problem with urine storage arises when the bladder fails to remain relaxed until an
appropriate time for micturition. Bladder overactivity has been classified as detrusor hyperreflexia
(1)11) or detrusor instability (1)1) on the basis of the presence or absence of a clinically detectable neu-
rologic disorder, however abnormal bladder behaviour in both situations is characterized by the same
urodynamic entity: involuntary detrusor contraction ( IDC) .
Detrusor hyperreflexia Detrusor hyperreflexia results from a variety of neuropathic disorders,
which cause damage to the neural pathways involved in the control of micturition. The clinical mani-
festation depends on the localization of the injury.
Suprapont ine lesions The cerebral cortex and the basal ganglia are thought to suppress the micturi-
tion reflex. Damage to the brain can induce bladder overactivity by reducing suprapontine inhibition.
Spinal COrd lesions Damage to axonal pathways in the spinal cord leads to the emergence of primi-
".M
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tive spinal bladder reflexes. A spinal cord lesion above the lumboMcral level eliminates voluntary and
supraspinal control of micturition, leading to bladder overactivity mediated by spinal reflex pathways.
There is an impairment of voluntary command of micturition and detrusor contraction on external
mechanical stimulation. Due to the disruption of the pontine reflex pathways, micturition contractions
are often unsustained and uncoordinated with detrusor-sphincter dyssynergia. Detrusor hyperreflexia
has been thought to result from a combination of decreased supraspinal inhibitory effects on the sacral
micturition reflex and re-enforcement of the segmental reflex by neuronal re-organization lollowing
loss of the excitatory descending pathways. An alternative theory is based on changes it« the allorent
input to the cord. The sensation of bladder filling is normally conveyed by amall myelinated 6-libers.
On the other hand, unmyelinated C-fibers convey noxious stimuli and seem to have little functional
significance in healthy humans. However, in the cat, chronic spinal injury results in automatic voiding
via a sacral reflex arc mediated by C-fiber afferent» rather than 5-fibers as in the healthy animal.
However, it is not known how C-fiber endings could adapt to become more mechano-sensilivo (1).
Enhanced C-fiber activity may also play a role in hyperreflexia in man, as intravesical administration
of Capsaicin (a neurotoxin) has been shown to reduce hyperreflexia and improve bladder capacity in
some patients with multiple sclerosis and spinal injuries (2).
DetrUSOr Instability There are some similarities between 1)11 and 1 )l which suggest that both may have
a neurological cause. Detailed neurophysiological testing and imaging has failed so far to show any such
deficit in idiopathic instability. In this context, non-neurogenic refers simply to the lact that a neurogenic
disorder is not evident. Given the complexity of neuromuscular control of vesicourethral function, a subtle
neurogenic cause (central or peripheral) cannot be excluded.
The origin of D I remains obscure. It may represent a failure of central control due to occult neural
processes, facilitation of the micturition reflex of unknown cause, or be due to a local factor in the de-
trusor itself. Undoubtedly, idiopathic DI represents a complex web of many contributing causes.
Opinions are divided as to whether the primary problem is in the detrusor (myogenic theory) or in the
nervous system (neurogenic theory).
Congenital ( immature bladder) The development of normal urinary control involves a complex
physiological relationship dependent on maturation and also behavioral influences. Persistence of
spontaneous instable detrusor contraction ( IDC) and the child's response to them play a key role in
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the origin of many pediatric urologio conditions. Enuresis. recurrent cystitis, vesicourethral reHux and
llinman's syndrome may all IK- manifestations of dysfunctional voiding patterns that are associated
with persistent 1)1. The degree of structural damage to the urinary tract depends on the frequency,
magnitude and duration of elevated intravesital pressures and the degree of obstruction that is pro-
duced by uncoordinated sphincteric contraction. Always taking into account that the main expression
ol the immature bladder is 1)1 persistence.
Various theories have l>een proposed to explain the cause of this dysfunctional voiding. The one that
best explains this condition in adults is that of McGuire and Savastano (3). They believe that the pri-
mary abnormality is 1)1 and that the detrusor sphincter dyssynergia that occurs develops as a result
of midden unanticipated detrusor contractility. Contraction of the pelvic floor-external sphincter com-
plex is a normal response to control urgent urination and results in a reflex inhibition of the detrusor.
When this becomes habitual over a period ol time the abnormal incoordination carries over to volun-
tary voiding, resulting in an intermittent urinary stream and residual urine.
Outlet obstruction The D l associated with outflow obstruction has long been recognized (4).
Approximately, it is present in (>()% of patients with benign prostatic obstruction. After prostatic trans-
urethral resection, the outlet obstruction disappears in two-thirds of patients. The best theory to
explain this has been based on an animal model. Urethral obstruction in the pig produces a similar
situation as seen in obstructed men by benign prostatic hypertrophy. Prolonged obstruction results in
detrusor muscle hypertrophy and connective tissue infiltration of the bladder wall. The combination
ol these changes and raised voiding pressures leads to a reduction in blood flow and oxygen tension
in the detrusor. Consequently, the detrusor is denervated through ischaemic nerve injury in the intra-
mural ganglia. Motor denervation of the detrusor causes a generalized increase in sensitivity of
smooth muscle cells through partial depolarization of the cell membrane (postjunctional supersensiti-
vity), which is said then to cause IDC (6).
Aging In the elderly, 1)1 is more common and the prevalence of urge incontinence increases with age.
independent of outllow obstruction or neurologic disorder. Older men have the same symptoms as
women, suggesting that LUT symptoms are a manifestation of aging in either gender. However, the boun-
daries between 1)1 and 1)11 are uncertain in this group of patients, since a;:r ,..--.n iated neurologic disea-
ses such as subclinical cerebrovascular disorders, autonomic neuropathy and chronic brain failure com-
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monly occur. Functional brain scanning using single-photon emission computed tomography has
shown that there is underperfusion of the cortex as a whole, and of the frontal lobes in particular, in
geriatric patients with 1)1. The underperfusion is particularly noticeable in tin- right supcM-ior lobe
(6). Thus. D I has been linked with both cognitive impairment and decrease«! perfusion of the fron-
tal lobes (7).
On the other side, abnormal cell to cell communications have been reported in aging people with HI .
blectron microscopy ol detrusor biopsies carried out by Klbadawi et al. rev r.ilrJ .i characteristic struc-
tural pattern. (8) The main leatures of this dysfunctional pattern are abuiui.iiii protrusions, junctions
and abutments which mediate in electrical coupling between muscle cells generating myogenic con-
tractions (9,10).
ID womi'i».Psychosomatic factors There is little current support for a psychological cause for DI
This has been based on the response to behavioral treatment and on the fact that certain psychologi-
cal factors may trigger urge incontinence, such as the sound of running water, a stressful event or an
event such as turning the key in the door. Although these events certainly do act as triggers, there is
no evidence that the mechanism is primarily psychogenic. By triggering the emotional motor system
in the brain, it is possible to influence micturition behavior (I 1.12).
Anatomical incontinence Approximately 30% of women with stress incontinence have concomitant
DI (26). After surgical correction of stress incontinence, DI disappears in approximately two-thirds
of these patients (27,28). A decreased inhibition of the pelvic floor or the urethra (due to pelvic floor
or urethra deficiency) can lead to increased efferent activity and subsequent detrusor overactivity.
The best support for this hypothesis is given by the clinical results of pelvic floor electrical stimulation
and rehabilitation. However, this pathogenesis remains to be proven.
There is also evidence that abnormal urethral relaxation may be the primary event which precipitates
IDC (13). The sequence of events in the normal initiation of voiding is still debated. Classically, de-
trusor contraction is preceded by an appreciable (all in urethral pressure. Wise et al. recently showed
that urethra! instability is strongly associated with the sequence of urethral relaxation prior to detrusor
contraction, whereas primary detrusor activity is almost exclusively associated with a stable urethra.
They described two different types of D I patients. Those with a pure detrusor (myogenic) problem,
with IDC not preceded by urethral relaxation and those without urethral relaxation prior to IDC,
27
Chapter 3
where the problem could be in the urethra or due to a premature micturition reflex. Urine in the pos-
terior urethra may result in the urgency to void and an involuntary bladder contraction. This may
occur by eliciting a urelhral reflex (13). However, studies of bladder pressure while injecting saline
into the proximal urethra have not provoked bladder contraction
Hypersensitivity disorders Evidence ha» been presented indicating that neuropeptides containing
sensory nerves innervate the human bladder (15,16). These sensory afferents are Capsaicin-sensitive
unmyelinated C-fibers and usually transmit sensations of bladder fullness, urgency and pain. Local
release of lachykinin and other peptides from sensory nerves in the bladder wall has been shown to
produce diverse biological effects such a» bladder smooth muscle contractions, facilitation of neural
transmission and increased vascular permeability (16). These properties of bladder sensory nerves
may suggest the hypothesis that in«, i' < ' illerent activity can induce bladder overactivity in patients
with hypentensitivity disorders. Sinn c ,i|.-.,iicin can suppress C-fiber sensory neuron activity, Alaggi
et al. instilled Capsaicin intravesically in patients with hypersensitive disorders of the LUT, showing
disappearance or marked attenuation of their symptoms. This result may support the hypothesis
above, but knowledge about the sensory function of the bladder is still limited (15,16).
Current theor ies Of bladder overact iv i ty Current thinking explains all forms of bladder overac-
tivity by two principal hypotheses: the myogenic and neurogenic theories. Separation into these two
groups is useful when attempting to explain the etiology of the disorder. However, the division is arti-
ficial, as muscle and nerve function are so intimately linked. A disorder in one wil l produce seconda-
ry changes in the other. Mechanisms of bladder overactivity vary with different etiologies (neuroge-
nic bladder, outflow obstruction, aging hypersensitivity etc). Therefore, it is not easy to find a com-
mon feature that underlies detrusor overactivity. In this respect. Brading and Turner (17,18) have
emphasized the myogenic changes (regardless of etiology)- On the basis of observations that denerva-
tion is consistently found in detrusor biopsy specimen from patients with various forms of D I , they pro-
posed that partial denervation of the detrusor may alter the properties of smooth muscle, leading to
increased excitability and increased coupling cells. Thus, local contraction that occurs somewhere in
the detrusor will spread throughout the bladder wall, resulting in coordinated myogenic contraction of
the whole detrusor. However, what actually triggers this local contraction is not resolved. Thus, as
ßrading stated, the changes in smooth muscle properties seem to be a necessary prerequisite for the
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production of IDC (18).
Bladder overactivity may be caused by decreased inhibitory control in the central nervous system,
reorganization of spinal reflex pathways, increased afferent activity, incre.iscd sensitivity to elVerent
stimulation in the detrusor or a combination of these (actors. Whichever (actors are involved, it is
important to note that IDC is actually induced by post-ganglionic neurons in the detrusor. From a cli-
nical point of view, it is clear that in any form of detrusor overactivity, anlinuiscarinic drugs um
improve symptoms, reduce urgency and increase bladder capacity. This may suggest that postgan-
glionic cholinergic neurons are activated, leading to IDC. Kven in the myogenic theory ol D l , the neu-
rogenic (actors are required (or trir . n M ")(\ Thus in the case of D l , some activation ot postganglinnic
neurons (cholinergic or purinerjju » nun uuur during bladder filling, whereas this activation can be
directly caused by an uninhibited micturition reflex (supraspinal or spinal) in I lie case ol D l I. Both neu-
rogenic and myogenic mechanisms may be involved in the pathogenesis ol bladder overactivily. Although
the cause of overactivity bladder is different in neurogenic bladder, etiology-related Dl and idiopathic D l ,
an activation of postganglionic neurons may finally produce the same effect on bladder behavior, IDC.
URGENCY-FREQUENCY SYNDROME
The urgency-frequency syndrome is another form of overactive bladder. It is characterized by an
uncontrollable urge to void, resulting in frequent, small amounts of urine voided as often as every 16
minutes. Patients report that they do not (eel empty alter voiding. Olten but not always, pain or dis-
comfort accompanies this condition. Incontinent episodes may occur but are not the primary com-
plaint. Urologie diseases related with this syndrome are: urethral syndrome, pelvic pain such as prosia-
todinia, orchalgia, interstitial cystitis. Also, several non-urologic diseases are related: irritable bowel,
proctalgia and anal sphincter instability.
From a urodynamic point o( view, these patients do not show IDC on provocative cystometry. Thus
they have been diagnosed as having sensory as opposed to motor urgency.
The etiology of irritative voiding symptoms such as urgency frequency remains unknown. Thus,
knowledge about pathophysiology is still fairly limited. Current theories have recognized this syndro-
me as a significant indication of increased fragility or excitability in sacral reflex neural regulation of
voiding. It is considered as the result from an imbalance between facilitatory and excitatory control sys-
tems causing a hvperexcitable micturition reflex. Pelvic floor spasticity seems to be a main consequen-
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ce provoked by augmentation of sensory input into the central nervous system (e.g.. peripheral inf lam-
mation) or a loss of intr insic central nervous system inh ib i tory circuits due to neural pathology (19).
EMPTYING DISORDERS „
Patient« w i th bladder empty ing problems can experience voiding symptoms (e.g. hesitancy, loss o f
force of the ur inary stream, decrease of the caliber o f the stream), incomplete void (significant volumes
of residual urine greater than 50 cc remaining in the bladder post voiding) or complete retention ( inabi-
l ity to initiate a void). Functionally, mictur i t ion is a result of two (actors, viz detrusor contraction and
urcthni l i < •••! i.uice. Therefore, bladder emptying problems can be caused by impaired detrusor contrac-
tion (weak in mi l i laddcr contraction) or bladder outlet obstruction (high urehtral resistance).
I loth can have organic or funct ional causes. Impaired detrusor contractions secondary fo benign pro-
stulic hyperplasia or high urethral resistance due to str ictures are examples of organic causes and can
be surgically treated. Functional causes means that organic defects cannot be demonstrated, so that
the treatment of these disorders very often does not address the cause. Detrusor hypocontract i l ty or
acontract i l i ly and/or spastic pelvic f loor syndrome might be responsible for fai lure to empty the blad-
der. The under ly ing pathophyaiology of these funct ional causes has not been clearly elucidated and is
supposed to In- mult i factor ia l .
BLADDER HYPO-ACONTRACTILITY
The acontractile detrusor is one that does not demonstrable contract during urodynamic studies.
Delrusor areflexia is defined as acontractility due to an abnormality of nervous control and denotes
the complete absence of centrally coordinated contraction. In cases where no neurogenic disease is
evident, the hypocontractility is considered as idiopathic.
Neurogenic hypo-acontractility (areflexia) Detrusor areflexia is the absence of spontaneous det-
rusor contractions in a patient with neurologic lesion. Bladder and urethral function become altered in
response to neurologic disease in a limited number of ways. Neurologic lesions produce a loss of func-
tion, through a decrease in facilatory nervous transmission. Such loss of function is characterized by
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paralysis of the tletrusor in those patients with lower motor neuron lesions. Patients with lumbosacral
lesions, such as cauda equina injury' or myelodisplasia are more likely to develop a flaccid bladder. In
such cases, facilatory impulses are inadequate to generate a detrusor contraction. Therefore intravesi-
cal pressure does not develop and voiding does not occur. ^ v * » ^ ^; ; • » t ; ,
Non-neurogenic bladder hypo-acontractility ldiopathic non-obstructive bladder hypo- u> anm-
tractilitv is a perplexing entity in modern urological practice. Some Functional disorder* during ilie
maturation phase, like poor voiding habits or forced toilet training, can become manifest over imu\
The desire to void is a sensation which, in the developed child, is incorporated into daily life »o that
voiding takes place at an appropriate time and place. Problems with training or psychological diffi-
culties can have a great impact on the results of training. Misuse of the pelvic lloor may cause a chan-
ge in dynamics of the lower urinary tract function. If the neural reflexes are not conditioned approp-
riately due to constant misuse (e.g. voiding by using abdominal muscle instead of relaxing pelvic floor
muscles), a permanent change in these neural reflexes may result. Since inhibitory reflexes .m- lear-
ned behavior during maturation of the nervous system, proper use of the pelvic floor is critical to pro-
per development of these behavioral reflexes (20). Some parents send their child to the toilet many
times, although the bladder may be empty. Voiding in these circumstances can only be achieved by
abdominal straining. As the child wil l be rewarded to produce even the smallest amount of urine, the
result may be an abnormal voiding pattern. The same is true when children receive negative feedback
related to voiding. Children with a lazy bladder void infrequently. They usually result in urinary tract
infection and overflow incontinence. I^ong-standing overactivity of the pelvic floor is thought to be
responsible for decompensation of the detrusor, leading to a noncontractile bladder. However, no data
are available to support this theory.
A mild degree of bladder weakness occurs quite commonly in older individuals. There is a clear and
significant reduction in detrusor contractility with age, both in women and in men. In tlx- absence of
previous obstruction, the detrusor is characterized at the cellular level by widespread degenerative
changes of both muscle cells and axons, without accompanying regenerative changes. These degene-
rative changes can easily explain the limited capacity of muscle cells to generate contraction, as well
as being an impediment of the neural mechanism that triggers it at the muscle cell level.
Chapter 3 : -D
PELVIC FLOOR MUSCLE-URETHRAL EXTERNAL SPHINCTER OVERACTIVITY.
The »acral micturition reilex is a positive feedback system that is poised to empty the bladder unless
acted on by inhibitory reflexes. Any deficiency in the inhibitory reflexes acting on the detrusor are
likely to result in bladder overactivity, including urge incontinence and urgency frequency. One of the
bent known inhibitory reflexes of the detrusor results from external sphincter contraction. Weaknesses
in tin- pelvic iloor that prevent sufficient contraction of the sphincter may, therefore, result in an unin-
hibited detrusor. The contrary is also true in patients with voiding dysfunction. If the pelvic floor mus-
cles and sphincter are telanically contracted, the detrusor is inhibited to the point of overfilling and
distending the bladder. . . , • . - •
Some cuses of voiding dysfunction VtMtOciated with some degree of hyperactivity of the pelvic floor
and external urelliiul sphincter muscles. These patients have a lack ol pelvic control based on the
observation ol their inability to localize the pelvic floor. Vapnek and Schmidt theorized that in these
patient* liiere in an over-inhibition of I he voiding reflex through a pathological reflex (21). Schmidt
believed iliai nouromodulation may function through directing the patient to relocalize the pelvic floor
and, hence, regain the capability of relaxing it and initiating voiding (22).
FOWLER SYNDROME
In I')8N. Kowler el al. described a syndrome in young women in whom urinary retention was the pre-
dominant clinical feature and electromyography (EMC) of the striated muscle of the urethral sphinc-
ter revealed abnormal activity (23). The KMC> activity is localized exclusively to the urethral sphinc-
ter and consists of a type ol activity that would be expected to cause inappropriate contraction of the
muscle in which it is found. The K M d activity has many features of myotonia, a condition in which a
striated muscle remains in a state of sustained activity following contraction. However, detailed KAAG
analysis shows there are significant differences and that sphincter activity consists of two components,
viz complex repetitive discharges and a decelerating burst. Why this type of EMG activity should
develop in llu- met lira I sphincter is unknown. The observation by Fowler that women with urinary
retention also often have policvstic ovaries raises the possibilitv that the activity is linked in some way
to an abnormal hormonal imbalance. Perhaps impaired muscle membrane stability results, allowing a
direct spread of electrical impulses throughout the muscle. Whatever the cause or nature of the abnor-
mal EMCi. urinary retention seems to be produced by an impaired sphincter relaxation. Although the
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hypothesis that urinary retention in these young women is the result of a primary failure ol relaxation
of the sphincter remains to be demonstrated, some indirect findings support this idea.
Evidence has been provided showing the existence of a group of women with an abnormally high
urethral pressure profile and obstructed voiding in whom ultrasound studies focusing on sphincter
volume showed local muscle hypertrophy (24-26).
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HISTORY OF THE DEVELOPMENT OF NEUROSTIMULATION
In 1878, Saxtorph reported intravesical electrostimulation in patients with an acontractile bladder and
complete urinary retention. Later Katona, Ascoli and Federici applied electrostimulation in patients
with chronic neurogenic retention and hyperrcflexia (1,2). In 1963, Caldwell developed a sphincter-
Htimulator to treat siren» incontinence (3). Clinically applied electrical stimulation is a phenomenon
dating from 1966 and was fully developed lor pain therapy (4). Since then, numerous studies have
been done in the field of functional electrical stimulation (FES). FES can be divided into neurosti-
mulation, mainly stimulating efferent», and neuromodulation, mainly stimulating afferents. The blad-
der muscle can cither be stimulated directly, on the muscle, or indirectly, via the nerves. The advan-
tage of indirect stimulation in that it can be tested before it is applied, as in neuromodulation and
Percutaneous Nerve Evaluation (PNK). Uuring fhis test, fhe nerves are temporarily sfimuJafed fo
evaluate these nerves. The direct neurostimulation of the detrusor was first performed by McGuire
(5). Afterwards Bradley developed transmittable stimulation of the detrusor in patients with neur-
ogenic bladder problems. Although short-term results were promising, long-term results were disap-
pointing, only being successful in 30-40% o( the cases (6-8).
After the peripheral nerve stimulation in animals was first reported by Giannuzzi in 1863 (9), several
series of animal testing started (10). Most of this research concentrated on stimulating the pelvic nerve.
Due to this stimulation, nerve fibrosis led to deterioration of these nerves and loss of Junction (11,12).
Stimulation of sacral nerves and conns medullaris was developed to electrically empty the bladder (13-
15).The bladder and sphincter were stimulated through the roots of the parasym pathetic S2-S4. This
resulted in high voiding pressures and residues, because sphincter and bladder are stimulated at the same
time. i.e. the sphincter is tightened and the bladder is contracted. This resulted in post-stimulus voiding:
when the stimulation was stopped, the sphincter relaxed and voiding would start (14-16). In 1969,
Brindlev developed an electrode for long-term stimulation of the spinal roots, and in 1972 the first patient
was implanted (17). The first paraplegic patients were implanted in 1978 and since 1986 a de-afferentia-
tion, or posterior rhizotomv, of S2-S4-5 nerves was routinely performed. This resulted in an enlargement
of the bladder capacity while hyperreflexia was abolished, thus continence could be gained (18).
During the sixties, intra-anal and intra-vaginal probes were developed to achieve non-invasive elec-
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trical stimulation of the pelvic floor (3). In experiments with this kind of stimulation, it was found that
stimulation ot the pudendal nerve could inhibit instable detrusor contractions (19,20). Studies have
indicated that stimulation of the afferent system activates the sympathetic inhibitory system of the
bladder and preganglionic motor neurons through a spinal inhibitory system (21). Ascending spinal
neurons, which project to the pons and cortex, are also inhibited. Thia could explain a decreased urge
sensation during stimulation. •.•.-.•• .^:,,.- - • •.-.;•...-. - ^
These findings form the basis ot the application ot sacral nerve stimulation through the third sacral canal.
This technique is performed in patients without neuronal disabilities, or in partial spinal cord injured
patients, although nowadays these patients are possible candidates lor this therapy. In patients with
symptoms ot urge incontinence or chronic urinary retention, neuromodulation is a therapeutic option.
In this treatment, electrical field stimulation is applied to the sacral nerve, mostly S3. Starting from
the fifties, interest went to the application ot electrical stimulation to bladder and urethral sphincter
to obtain continence or bladder control. The development ol a transistor, shortly alter the Second
World War, facilitated the development of cardiac muscle stimulation (22). Shortly aller this, the
development of urinary pacemakers began, at first with little success. However, (iiles llrindley in
London and Emil Tanago together with Richard Schmidt in San Francisco developed useful func-
tional electrostimulation (17,23). They are therefore the pioneers in the field of useful functional uri-
nary stimulation systems (24).
Neuromodulation This procedure was introduced in the late eighties and involves two step«. First a
stimulation electrode is introduced in the sacral canal, close to the S3 nerve. Secondly, if a good result
is obtained during the test period, a permanent implantation is undertaken. Although already a lot of
research has been done on neuroanatomy and neurophysiology, in particular in animals, the exact wor-
king mechanism is still obscure and therefore neuromodulation is an empirically based therapy.
Tanago and Schmidt treated 20 patients with therapy resistant urge incontinence, and achieved an
average reduction of 90% of the symptoms in 70% of the patients (25).
Working mechanism of neuromodulation A first hypothesis was proposed by Schmidt, who sta-
ted that neuromodulation changed the spastic behavior of the pelvic floor, which was presumed to be
the cause of most functional bladder disorders (26). The electrical stimulus was thought to activate the
pudendal nerve, contracting the pelvic floor musculature and external urinary sphincter. This con-
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traction should result in an inhibition of the detrusor muscle and therefore produce a detrusor relaxa-
tion. This means that, when increasing stimulation is applied on the nerve, improved contraction of
the muscles is obtained (»neurostimulation), resulting in more efficient detrusor inhibition (25). The
nerves projecting to the pelvic floor musculature are large diameter nerves. Because of their large dia-
meters, dcpolariHation occurs at a lower amount of energy applied to the nerve, compared with smal-
ler diameter autonnmic nerves, especially unmyelinated nerves. This implies that the large somato-
Ncnsiiry nerven in the pudendal nerve are first excited (25,27). After implantation, it is important that
the electrode is fairly close to the nerve. If the distance is too far, a higher amount of energy is applied
lo .i larger field. Then the nerves in the proximity of the electrode, e.g. unmyelinated nerve fibers and
small ö-fibers, wil l be stimulated, causing pain (27).
Nowadays it in clear thai neuronal bladder inhibition, through sacral neuromodulation. is not cau-
sed by pelvic floor contraction, but through afferent stimulation. Animal experiments show that
pharmacological paralysis of ilu- pelvic floor does not reduce bladder inhibition during electrosti-
mulation (28).
Home, bladder inhibition is not the result of activating somatosensory efferents of the pudendal nerve
(10). In addition, stimulating the afferent» of the pelvic floor through the pudendal nerve results in
neither bladder stimulation nor inhibition (28). Bladder excitation was found during stimulation of
pelvic nerve afferent« Irom the bladder and urethra as well as pudendal nerve afferents from the uri-
nary sphincter. The bladder was inhibited by pudendal nerve afferents from the clitoris and the glans
as well as pelvic nerve afferents from the anorectal region (10.28). Furthermore, after chemical de-
efferentiation of the sacral nerves that innervate the pelvic floor, the effects of electrical stimulation
on the bladder were inhibited. This also indicates that sacral neuromodulation has a direct effect on
the sacral afferent nerves and that it is not a reflex mediated by the pelvic floor (28).
Schultz-l^ampel holds the ß-fibers of the sacral nerve afferents responsible for the electrically induced
inhibition of bladder contraction (10). Pudendal afferent ß-fibers from the urinary sphincter and/or
pelvic floor induce electrical inhibition of bladder contractions (10). As these fibers are large in dia-
meter, these nerve cells can be depolarised with minimal amounts of energy. Therefore, neurostimula-
tion should not be applied through muscle contraction, nor should excess energy be applied to pro-
duce depolarisation of the smaller nerve fibers, like ß, B and unmyelinated C fibers, which results in
a painful sensation. These fibers are also responsible for bladder contractions, induced by bladder dis-
•(0
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tension or chemical excitation. These are conveyed by the pelvic nerve. Therefore, stimulating the
pudendal afferents can inhibit detrusor contractions (29). Stimulating the large-diameter aileron!
fibers can inhibit the parasympathetic motor neurons (21). m «j «-«« T, u *,; : i
Sacral neuromodulation inhibits reHex afferent input from the bladder. The stimulation of afferent
nerves might result in inhibitor)'or stimulatory reflex activity (10). ., H> , . .
In patients with chronic retention, voiding is believed to take place through a rebound response of the
bladder. During neuromodulation the bladder is inhibited. If this inhibition is stopped, by turning off
the electrical stimulation, a rebound contractile effect on the bladder can be measured (.30,31).
Surprisingly, most of the patients do not need to turn off the stimulation to be able to void (32). It was
found that patients with urinarv retention had a significantly stronger bladder contraction and lower
urethral resistance after six months of neuromodulation. Furthermore, the neuropalhology ol chronic
retention, even when it is seen after pelvic surgery, remains obscure. Detrusor hypocontractilily or
acontractility and/or a spastic pelvic floor syndrome might be the cause of bladder-emptying problems
(26,33-35). In 1988, Fowler et al. described a syndrome in young women in whom urinary retention
was the predominant feature and in whom the electromyography (KMG) ol the striated urethral
sphincter revealed a striking abnormality. Due to this abnormality, the women could not relax I he
sphincter and retention would therefore result (36,37).
Although the pathophysiology and aetiology of voiding dysfunction has not IHTI I clarified totally, it
can be influenced successfully by sacral neuromodulation.
Percutaneous Nerve Evaluation (PNE) Before a patient can be provided with an implanlable sacral
nerve stimulator, first a trial period is applied. Not every patient will benefit from thin therapy. A pro-
visional test can establish whether patients are likely candidates for successful implantation. During a
3-5 day trial period, the sacral nerve is stimulated with a temporary electrode (38).
I f a patient is a candidate for sacral nerve stimulation, it is suggested that a voiding diary is kept. This
has to be done to identify the voiding complaints and to compare the voiding pattern before and
during stimulation. I f there is a decrease of voiding complaints of 50% or more, the percutaneous
nerve evaluation test is considered to be successful. Then the patient is a candidate for implantation.
If the test fails, another test can be performed. If this fails again, the physician should find another
alternative or try a 'two-stage implant' (see this thesis, chapter 6). If a patient is very nervous about
taking this test, diazepam can be administered orally, one hour before testing.
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P N E tent ( w e pages 134 and 135) o H U
1. Local izat ion and ident i f icat ion of the sacral foramina S2-S4.
2. Probing the sacral foramen. =«;<;
3. St imulat ion o f the sacral nerve. •••,•• . ;,^*
4. Ins i r i i i l ion of the patient. ..•...->:.-.
To per form a I 'NK, the patient should be in a prone posit ion on an examinat ion table w i t h the lumbar
spine and sacral bone in one hor izontal plane. Bolsters can be used to obtain a correct posi t ion, the
hips «hould be in « slight antef lexion (30°) . A p i l low should be under the feet to a l low free movement
ol the feel. There should be a good exposure of the anus and per ineum. To obtain this, the but tocks
are spread w i t h tape. Also the feet and the calves should be exposed.
Then the sue n i l foramina can be localized. Several techniques can be used to localize the sacral fora-
mina through surface markers (39,40). We prefer the fo l low ing method:
Af ter the anal region has been exposed, palpate the iliac crest and the spinous process o f L4 and L5.
Palpate the coccyx, the sacrococcygeal joint and the sacrolumbar jo int . M a r k these bony landmarks.
A line ivs d rawn between the spinous process of L/i and the sacrococcygeal jo int , exactly in the m id -
l ine to the natal cleft. Then a line is placed at the sacrolumbar jo int . In the middle o f the cranio-cau-
dal line between the sacrolumbar joint and the sacrococcygeal, a transverse l ine is d rawn . One f inger
10 the right (+ / . 1.6 cm) or one f inger to the left o f t h e midl ine is the puncture location for the S3 fora-
men. The puncture location to reach the foramen o f S2 is located one f inger or approximately 1.5-2
cm cranial o f the location o f S3. The same goes for S4 in the caudal d i rect ion.
11 these puncture sites are marked, a large region is to be desinfected, approx imate ly 30 cm sur roun-
d ing the S3. The patient is draped on the superior side and both lateral sides. The caudal side should
not be covered, because this wou ld prevent observation o f t h e motor response at the per ineum.
Af ter this, the patient can be tested. First, the puncture site must be anaesthetized. This is done w i t h
l idocaine. First the skin is in f i l t ra ted, then the periost is in f i l t ra ted, near the foramen. Avo id in f i l t ra-
t ion of the foramen, as this wou ld paralyze the sacral nerve, resul t ing in no response.
Then the needle can be posit ioned. The needle is inserted perpendicular to the bony surface o f the
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sacrum, m a 60" angle to the skin (lumen of the needle facing caudal). Then the S3 foramen can bo pro-
bed. Try to find the cranial and medial rim of the foramen. The sacral nerve lies 1-4 cm below the fora-
men opening in a small mediocaudal area of the lower medial quadrant ul ,he foramen. The needle
must be in a correct plane, not facing medially nor laterally, as it is inserted into the sacral canal (43).
J.
After the needle is inserted into the S3. testing can take place. A sterile mini test-hook is connected to
the superior part of the test needle, and the amplitude of the test stimulator is gradually increased.
Now the patient must be observed to see if there is bellow-like contraction of the levalor-ani muscle
and a plantair-flexion of the first digit of the ipsilateral foot. This bellow-like contraction results in an
elevation of the anus, due to a contraction of the pelvic musculature. In addition, the patient must be
asked what he feels and at which location. A pulling like sensation should be felt in the anal, perine-
al, scrotal, and/or vaginal region. The place of the needle can be »lightly adjusted in depth or angle to
obtain the best response. I f good responses are obtained, the lead can be inser.ed through the needle
and the nerve is tested again. Afterwards, the lead is fixed to the patient with a .,.,„ , , , , , „ , dressing.
A small opening is made for drainage of blood. Cover this hole with a gauze and cover the gauze with
another dressing. Extra dressing is used to minimize lead migration. Then .he electrode and ground
pad are connected to the test stimulator for a trial period of 3-7 days.
The patient is instructed how to use the test stimulator. It is advisable to avoid bending of the back or
strenuous household chores, to minimize chances of lead migration. Also cycling should be discoura-
ged. In addition, the patient is instructed to complete the voiding diaries. After 3-7 day«, the patient
is seen again and the test period is evaluated.
A. In urge incontinence, a reduction of at least 50% of the following parameter».
1. incontinent episodes
2. pads usage
3. urge sensation
B. In urinary retention: micturition with a maximum of 50 cc retention.
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C. In urgency frequency syndrome patients, a decrease of frequency to fewer than 8 times daily
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Implantation of the sacral nerve Stimulation system During implantation, no muscle relaxants
must be given, because IIIIH will abolish muscle response to the stimulation. The patient is then placed
in a prone position, with 30 degrees anteilexion of the hips and knees. When the patient is draped, use
transparent drapes, HO an to be able to see the muscle reactions to the stimulation. Then, the procedu-
re lor the PNI i as referred to above is followed. If good responses are obtained, a midline incision from
S4-SI in made. The fascia is freed of subcutaneous tissue on the site of implantation. Then a parame-
dian incision i» made through the paraspinal mutcle. Next, the S3 foramen is located and probed with
the tent needle. Stimulation in applied by the mini J-hook and the nerve is tested for response. I f good
pelvic floor re»|» n . .ire obtained with or without toe response, the lead is inserted in the third sacral
foramen perpendicularly. Puncture in the medial superior quadrant of the foramen is done, followed
by insertion of the lead in this quadrant. The nerve lies in the inferior-medial part of the foramen(43).
The lead it* slightly curved to follow the curvature of the nerve laterally- Some authors have proposed
inserting the sacral lead as far medially as possible in the foramen and turning the bend in the lead
medially, so as to prevent post-operative leg pain (41). If the lead is in place, it is anchored to the
periosteum of the sacral bone. The four electrodes on the lead are tested for proper response. After
(hat, all four electrodes are tested lor their response. Then the lead is connected to the implantable
pulse generator (IPG). An extension cable is tunneled subcutaneously to the I PC. The IPG can ei-
ther ho implanted in a subcutaneous pocket of the anterior abdominal wall or in a subcutaneous poc-
ket of the superiolaterul buttock.
In our clinic, we recently started to implant the IPG in the gluteal region, in the top lateral buttock
quadrant, the same location where intramuscular injections are given. We prefer buttock placement of
the IPG, because the operating time is reduced by 1 hour, because repositioning of the patient may be
required and, nuireove, because a short subcutaneous tunnel is needed and only two instead of three
incisions are required (chapter 10).
POSt-Operative IPG management The day alter surgery, if the patient feels well, the IPG can be
turned on. Normally, wo start with unipolar stimulation. This means that the case of the IPG is posi-
tively charged and one of the *4 electrodes of the lead in the sacral foramen is negatively charged. It is
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also possible to apply bipolar stimulation. This means that the case of the l l 'G has no charge and one
of the electrodes is positively and one is negatively charged. In unipolar stimulation, a larger electri-
cal field is active, stimulating a larger part of the sacral nerve. So in unipolar stimulation it is possible
that side effects like pain or sensations in other places than the anus, labia, perineum, vagina, testes or
penis are felt. In that case patients mostly complain about pain or sensations in the leg or buttock. II
this is the case, one should switch to bipolar stimulation, which results in a smaller electrical field, iluis
reducing side effects.
As it is possible that in the first weeks after surgery the lead slightly moves, at first unipolar stimula-
tion should be applied. Because the nerve is in a larger electrical field, slight movements ol the lead
will not cause different sensations and the correct nerves will still be depolarised.
When stimulation is started, it should be fell close to or in the midline of the anus, vagina, labia, peri-
neum, testes or penis. The amplitude should be set just so that the patient can feel the stimulation in
one ore more of the above-mentioned regions. The patient should feel a tingling or throbbing sensa-
tion. This sensation should never be painful. If the sensation is not felt in the correct position, other
electrodes (0-3) should be switched to negative to obtain the correct position of the stimulation, a I no
in the unipolar setting. If there are more possibilities, the setting with the lowest amplitude should be
chosen.
I f unipolar stimulation causes uncomfortable side effects switch to bipolar stimulation. The electric
charge of the case should be turned off and one of the electrodes of the lead should be switched to
positive, another one should be negatively charged. If only one electrode is negatively charged, I here
are twelve possibilities to establish a bipolar setting. It is not advisable to set more electrodes negati-
ve, as this uses more battery power, reducing battery life.
Stimulation of the nerve is pulsed. The amplitude of the pulse is in volts, which we have just discus-
sed. The width is called the pulse width and expressed in microseconds. The amount of space below
this curve is the amount of energy applied to the nerve. This energy is needed to depolarize ihe nerve,
causing the desired effect. From the point of view of battery life, a pulse width of 210 (is it* advisable,
though slight variations are allowed. By changing pulse-width, it is also possible to diminish side
effects, or pain. The pulse-width should be between 60 and 270 (is, but slight variations of pulse width
cause large changes in battery life. Because a change in pulse-width causes a different amount of ener-
gy to be applied to the nerve, the amplitude may have to be adjusted to keep the energy at the same
level (27).
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The frequency of pulses, viz the rate, can be adjusted, initially, a pulse frequency of 10-15 Hz is advi-
sed, although we normally use 10 Hz. Animal studies have shown that stimulation at 5 Hz induces an
increase in bladder pressure due to stimulation of large myelinated efferent fibers. At 10 Hz, bladder
inhibition ia induced by stimulation of Aß afferent fibers (10). If the frequency is set too high (more
than 19 Hz), pain may be induced by stimulation of the thinner AS, B and C fibers. Higher frequen-
cies may cause nerve damage (42).
The parameter continuous or cyclic stimulation can cither be used if a patient gets used to the stimu-
lation very easily or to save battery life. If we apply the cyclic mode, we usually put it 10 seconds on
and 2 seconds off with a soft-start time of 1 second. The latter means that the voltage is increased to
normal amplitude in one second and not all at once. Of course, other configurations are possible in
on/off time.
It is advisable m apply the continuous mode in the first months after surgery, before switching to
cyclic mode.
-(6
Chapter 4
REFERENCES
1. Ascoli R. Le traitement des vessies neurogcnes. A7«i ( W W < 1%5: 33:76-83.
2. Katona F. Stages of vegetative afferentiation in reorganization of bladder control during intrnvcsic«! electro-
therapy. T/W//»/ 1975; 30:192.
3. Caldwell K. The electrical control of sphincter incontinence. /«i/i«W l%3: 11:174-176.
4. Melzack R. Wall P. Fain mechanisms: a new theory. .SV«vi<r I9(>5; 160:971-979.
5. McGuire WF. Response of the neurogenic bladder to various electrical stimuli (thesis): /V/>/. ,./\V«/y /Wmu«
( m i y S t W <>//»/«•<>; 1955.
6. Bradley W. Wittmers U Chou S. French L. Use of a radio transmitter receiver unit to. I ho treatment of neuroge
nie bladder: a preliminary report. ./<>/'AVwwtf/ywy 1962: 19:782-786.
7. Bradley W. Wittmers L. Chou S. French L rurther experience with the radio transmitter receiver unit lor the
neurogenic bladder. ./ .'/ .\>///w«/y.vv 19(>3: 20:953-9(>().
8. Hald T, Meier W. Khalili A, Agrawal G. Benton J. KantrowiU A. Clinical experience with a radio-linked bladder
stimulator. . / n / 7 W 1967; 97(l):73-78.
9. Giannuzzi M. Nerfs moteur de la vessie. ./<>«rW<><• Ai /»A\*«W^/i- de Hrown-Sequard 1863; 6:22-29.
10. Schultz-Lampel D. Neurophysiologische Grundlagen und klinische Anwendungen der sakralen
Neuromodulation zur Therapie von Blasenfunktionsstörungen (Habilitationsschrift). Wuppertal:
Fakultätsklinik Witten/Herdecke; 1997.
1 1 Hald T. Argawal G. Kantrowitz A. Studies in stimulation of the bladder and its motor nerves. .S"«/v/<-ry 1966; 60:
8-48-85(1.
12. Bradley W. Timm G. Chou S. A Decade of experience with electronic stimulation of the micturition reflex. / W
/«/ 1971; 26:83.
13. Eidelberg E. Bors E. Woodbury C. Brigham A. Effect of electrical stimulation of dorsal and ventral spinal cord
roots on the cat's urinary bladder. /Wo«/«/ /«/«TWH/WM/*« 1974; 29(6):375-381.
14. Jonas U. Heine H. Tanago E. Studies on the feasibility of urinary bladder evacuation by direct spinal cord sti-
mulation. I. Parameters of most effective stimulation. Aitr../ / W 1976; 13(2):142-150.
15. Jonas U. Tanagho E. Studies on the feasibility of urinary bladder evacuation by direct spinal con! stimulation.
I I . Poststimulus voiding: a way to overcome outflow resistance. //nr.</ f'/W 1975; I3(2):I51-I63.
16. Brindley G. An implant to empty the bladder or close the urethra../«,/A'«i«/. AW,M,/,v,rrv W /tyrtoii//? 1977;
40(4):358-369.
17. Brindley G. Experiments directed towards a prosthesis which controls the bladder and the external sphinc-
ter from a single site of stimulation. In: /'nwmtoi*. <»//k to^/%««% 5 ^ / y , 46th Meeting; 1972;
Chapter 4
Liverpool, Kngland; 1972.
18. Brlndley G. I lintory of the sacral anterior root stimulator, 1969-1982. AVU/VM/W<iW f W y / i 1993; 12(5):485-
• 4 8 6 . • - • . , , - , : • < . , , j , ,- - , : : , v , . •-
19. Fall M, Erlandton B, Sundin T, Waagttein F. Intravaginal electrical stimulation. Clinical experiments on bladder
minimum ./ ,./7 '/•«/,/«<> A'f/»/wn/ I 'J7H h; Suppl 44(part -4):4 I --<8.
20. Fall M, Llnditrom S. Klcclricul stimulation: A physiologic approach to the treatment of urinary incontinence.
/"W ('///» AW/> /I/« 1991; 18:393-407.
2 I. Llndstrom S, Fall M, Carl**on C-A, Erlandson B-E. The neurophvsiological basis of bladder inhibition in respon-
se to inlraviigimd electrical stimulation. ./ /'/•<>/ 1983: 120:405-410.
22. Hald T, Bradlty W. The urinary bladder. Haliimore/U>ndon: Williams and Wilkins: 1982.
23. Schmidt RA, Brutchinl H, Tanagho EA. Feasibility of inducing micturition through chronic stimulation of sacral
root*. /'/•../.../.¥ 1978; I 2 H M 7 I - 7 .
24. Karrebroeck van P. Nog inuar net... Maar loch. In: 1997.
2/i. Schmidt R. Advance» in genitourinary neuroiitimulation. AVw/YVM/yerv 1986; 19(6): 1041-1044.
2(>, Schmidt R. Applications of ncurostimulation in urology. AV/Z/VM/W f^/Wv« 1988; 7:585-592.
27. Glaaton C. Klectrophysical fundamentals of neurostimulation. inW<'./<>/'f W 1991; 9:110-113.
28. Lindstrom S, Sudsuang R. h'unclionallv specific bladder reflexes Irom pelvic and pudendal nerve branches; an
c\|>iTnncnlal study in the cat. AV«n>//n>/(>i/vI'm' /Vt«rV'<""<<*-' 1989; 8:392-393.
2'). Winter D. Keccpior characteristics und conduction velocities in bladder afferents. 7. <>/7'.»_v«'A<<i/w A«*.'t-<7A-i6
1971;8(3):225-23ft.
30. Thon. Gruenwald. Neuroütimulation. /Vv/oyy 1993:295-302.
31. Schultz Lampal D, Jiang C, Lindstrom S, Thuroff JW. Experimental results on mechanisms of action of electrical
ncuroimululation in chronic urinary retention. IfW<>./1»/"/ W 1998; 16(5):301-4.
32. Bosch, Groan, Essink-Bot, Krabbe, Seerden, Hout V. Sacral segmental (S3) nerve stimulation as a treatment for
urge incontinence due to dclrusor instability: Qualitv ol lite analysis and cost-cftectiveness. ./ /'n»/ 1996;
f>94A (ft suppl): 155.
33. Everaert K. Plancke H, Lefevre F, Oosterlinck W. The urodynamic evaluation of neuromodulation in patients with
voiding dysfunction. /Jr./ / W 1997; 79:702-709.
3-1. Gruenewald V, Hoefner K, Becker A, Krah H, Gonnermann O, Jonas U. Clinical results and complications of chro
nie sacral neuromodulation alter lour years ol application. In: .-I/IIHM/zrwWMy <»/7*V i/i/«'/yi<i//«>/i«j/«-<»/?///f<'»ir
.'.v/iVv.' 199(i 27-30 August; Athens: 1996.
3ft. Schmidt, Kaula. Sacral ner\ e root stimulation: Screening efficacy in management ot pelvic pain. .-J
{W<y<<'w/<i<i>f«y«i/ii>M 1996; 594A.
•«8
Chapter 4
36. Fowler a , Christmas TJ. Chappie CR. Parkhouse HF. Kirby RS. Jacobs HS. Abnormal electromyographic activity of
the urethral sphincter, voiding dysfunction, and polycystic ovaries: a new syndrome? ßr/*/<•<>./ 1988; Dec 3;
297(6661): 1436-8.
37. Goodwin R. Swinn M. Fowler C. The neurophysiology of urinary retention in young women and its treatment
by neuromodulation. I I W 7 f W 1998: 16:305-307.
38. Hassouna. Elhilali. Role of sacral root stimulator in voiding dysfunction. IIW«'./ T/W !*)*)!: MA-H8.
39. Siegel SW. Management of voiding dysfunction with an implantable neuroprosthesis. /#<• / Wiy/c CVHHI'.- «»/
A'or/A/Iwir/.w 1992: 19(l):163-70.
40. Hasan S, Shanahan D. Pridie A, Neal D. Surface localization of sacral foramina for neuromodulation of bladder
function. An anatomical study, /w/r { W 1996; 29:90-98.
4 1. Swinn M, Schott G. Oliver S. Kitchen N. CJ F. Leg pain after sacral neuromodulation: anatomical consideration!,
ßr./ f W /flfcTTM/iiww/ 1999; 84(9): 1113-1115.
42. Agnew WF. McCreery DB. Bullara LA. Yuen TGH. Kffects of prolonged electrical stimulation of pe ripluial nerve.
In: Agnew WF, McCrecry DU. editors. Art//v*//>/w/Ac.v.':./«/K'rf/in'/i/rf/.'/««'/<•»<. Prentice Hall, Knglewood
Cliffs. New Jersey: 1990. p. 148-167.
43. Mersdorf A, Schmidt RA, Tanagho EA. Topographical-anatomical basis of sacral ncuroitimulation: neuroanato-
mical variations. 7 ^ ./«wrmj/ ,i/Tn»Äyy 1993; 149:345-349
49
m. J . ASSFh
WSEV NEUROMODULATION OF SACRAL NERVES FOR INCONTINENCE AND
VOIDING DYSFUNCTIONS Clinical Results and Complications
P .T. Mijs I R. A. Ji
Department of (/
1/niVers/fy Wosp/fa/ /MT.
f/»e /Vether/ands
:72-76, 1993
51
Chapter 5
NEUROMODULATION OF SACRAL NERVES FOR INCONTINENCE AND VOIDING
DYSFUNCTIONS
/*•«/.< «'//A /r//vi«7V>ry «»/W/iy f
//i .wm
we«/ /// //;<•//• ///<//« .^y/N/)/«wi.i » i / k r rt m c A f l /*>//«»«•-«/» <>/" / ^ //><>///i&<. /// //r</«'-/«<'<»rtA'w«/ /'«//«'«/.' /^<* /;«////»<•/• <>/"
Introduction Nfuromudultttion of the sacral nerves is a new treatment form for voiding dysfunctions,
such as incontinence, urinary retention and chronic pelvic pain (1-3). Especially patients who did not
respond to the common therapies, and in whom disturbance in reflex coordination between the blad-
der, sphincter and pelvic floor is suspected, might benefit from neuromodulation.
Chronic electrical stimulation of a sacral nerve (usually S3) modulates the pattern of sacral reflexes
and can thus restore the normal balance between these reflexes.
An implantable neuroprosthesis for neuromodulation is currently under investigation. The first clini-
cal results are presented.
Patients and Methods A neuromodulation system (Itrel pulse generator, Itrel lead extension and
Pisces Quad foramen electrode, Medtronic, USA) was implanted in 23 patients after they had had a
successful percutaneous test neuromodulation (fig. 1). AH had refractory urinary symptoms, the main
symptom being urge incontinence in 16 patients, urgency and frequency in 1, retention in 3 and chro-
nic pelvic pain in 3 patients (table 1).
At protocol entry the workup consisted of a general and urological history, physical examination,
cystoscopy, plain abdominal X-ray, kidney ultrasound, voiding cystourethrogram and a complete uro-
dynamic examination (flowmetrv. urethral pressure profile, filling cystometry, pressure How, and 7-
hour ambulant urethrocystometrv).
Symptoms were recorded in diaries before, during and after the test neuromodulation, and during fol-
low-up after implantation. Urodynamic evaluation was repeated 6 months after implantation.
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Table I. /'«//>«/ ivirt
A g t , years
JMwn 46
Range 25-67
Sax
Female 16
Male 7
etiology
;'Naurogenic 5
Pelvic surgery 5
Bladder/prostate surgery 11
Main symptom
Incontinence 16
Urge/frequency 1
Retention 3
Pelvic pain 3
Median follow-up
!-20 months I.'
11, 9-20 months li>
Itrel II, 2-7 months 5
In the first 15 patients the Itrel I stimulator was implanted, which only enables telemetric resetting of
the stimulation parameters at a fixed contact point on the electrode. In the next 8 patients the impro-
ved Itrcl 11 version was used, which enables telemetric switching between the 4 contact points (fig. 2).
Stimulation parameters were: unipolar, monophasic, rectangular, pulse width 60-210 u, pulse rate 5-10
Hz, amplitude 0.5-4 V. Stimulation was either continuous or cyclic, for example 10s on and 2s off.
Results Fourteen patients had a good result, a more than 90% improvement in their main symptom:
9 incontinent patients are dry; I urge patient has a normal voiding pattern; 2 retention patients void
without residual urine, and 2 patients are free of pain (fig. 3).
Five patients had a partial, but still more than 50% improvement. Two urge-incontinent patients still
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experience some urgency. I incontinent patient has been cured of her frequency but still looses drop»
of urine, and 1 patient is still stress-incontinent, being cured of the urge incontinence. Finally I patient
with urinary retention can void now. but with residual urine varying from 100 to 200 ml.
Three patients had a bad result. One urge-incontinent patient never had a good response after the
implant. She had an excellent result at the percutaneous test, but with the implant the stimulation
response could not be reproduced. Two urge-incontinent patients had secondary loss of the therapeu-
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Table 2. (Vw;/>//<v///'(W.i
DeWce re/afed n /Vof deWce re/afed n
Electrode migration 2 Urinary . tlon 3
Isolation defect 1 Cerebrovaicular accident 1
Stimulator defect 1 Wound Infection
Pain/diKomfort '>
tic etlect, although the pelvic Moor response remained.
One patient with ileocystoplasty, on self-catheteri/.ation for total retention suffered from chronic pel-
vic pain, which responded very well to neuromodulation. When the ileum patch was removed from
(he bladder, neuro-modulation was effective again, now against pain, urgency and frequency.
Unfortunately the good result was lost soon after, due to a defect in the isolation of the electrode.
Recently the defective system was totally replaced because a percutaneous test showed that neuro-
modulation was still successful. At a first follow-up visit the patient reported less frequency and pain.
However, in figure 3 this patient is still in tin- bad' group.
For the incontinent patients the average number of pads used per day went down from 4.5 before
implantation to 1.8 afterwards. The number of leakings per day was reduced from 7.4 to 1.5, and the
mean voided volume increased from I 18 to 207 ml (fig. 4). Urodynamic evaluation in the incontinent
patients showed an increase in bladder volume at first contraction from 80 to 167 ml. an increase in
bladder volume at the end of filling from 13A to 227 ml, and a decrease in bladder pressure at the end
of filling from M to 23 ml (fig. 5).
Complications are listed in table 2. Several re-operations were done. A stimulator had to be replaced
because of a malfunctioning on-off switch (magnet-controlled). After several corrections a complete
system was replaced because of an isolation defect. Repositioning of the electrode was done 3 times,
because of migration (n - 1) and faulty positioning at implant (n = 2).
In the Itrel 1 group, the stimulated contact point on the electrode was changed 8 times, a minor re-
operation under local anesthesia, h'or the Itrel I I pulse generator this procedure can easilv be done
with an external programmer, without the need of re-operation.
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Discussion 1/rine storage and voiding are regulated at several levels of the nervous system. The mic-
turition reflex, descending from the pontine micturition center to the sacral efferent centers for the
pelvic nerve and the pudendal nerve, is thought to have a threshold (4). This threshold is set lower or
higher by many afferent nerves, coming from the conscious and unconscious cortical levels, the lim-
bic system, the peripheral organs in the pelvis like the bladder, sphincter and pelvic floor. Probably al
the sacral level the same thresholds exist, again with many facilitating and inhibiting inlluenoes upon
them. Several sacral reflexes are known, either stimulating or inhibiting sacral micturition center and
Oluf's nucleus for the pudendal nerve, e.g. the pudendo-anal reflex and the pudendo-detrusor reflex
(5,6). The pelvic floor plays an important role in this system of sacral reflexes. At least the activity
state of the pelvic floor influences the sacral level of the neural network controlling bladder functio-
ning, but most probably afferents from the pelvic floor ascend to the pontine level too. An activated
pelvic floor inhibits the detrusor, explaining the efficacy of pelvic floor excerciaes, biofeedbaik and
external stimulation in treating urge incontinence. Also activated afferent fibers in the pudendal nerve
inhibit the detrusor, again explaining the efficacy of external stimulation (7,8). With neuromodiil.nion
efferent fibers to the pelvic floor as well as afferent fibers in the sacral nerve are stimulated.
Myelinated somatic afferents will be stimulated more than the thinner parasvmpathic afferenlH (9).
There is still debate on the question of whether it is the activation of the pelvic floor, with subsequent
amplified and more physiologic afferent impulses, that is essential for neuromodulalion to be effecti-
ve, or the direct stimulation of the afferents.
Stimulation of S3 is optimal in most patients. S3 contains sensory fibers from the genitals and peri-
neum, afferent and efferent fibers from the anterior part of the levator ani and the urethral sphincter,
and autonomic fibers from the detrusor. Stimulation of S2 causes too much exorotation of the leg, with
mainly a contraction of the superficialpelvic floor. S4 projects more on the posterior part of the leva-
tor am with sensations around the anus.
With neuromodulation a weakened pelvic floor gets stronger. Patients become aware of (heir pelvic-
floor and learn how to use it. For example, by correcting a hypoactive pelvic floor, detrusor instabili-
ty can be treated. On the other hand, by correcting a hyperactive, spastic pelvic floor, voiding pro-
blems, urinary retention and pelvic pain may be treated.
Neuromodulation developed out of the neurostimuiation program for spinal cord injuries at I he-
University of California, San Francisco (10). A multicenter phase-2 trial has been going on in the
USA and Europe since 1990.
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The first clinical results ol the largest Kuropean group of patients from one institution are presented
here. 63 patients with urge incontinence (n » 39), urgency (n • 4), retention (n = 9) or pain (n = I I )
had percutaneous test neuromodulation. In 28 patients, a more than 50% improvement in their main
symptoms was teen. This is in accordance with earlier results by Schmidt and Tanagho (10).
Depending on patient selection, in 20-50% of the patients neuromodulation will be successful.
Percutaneous testing is absolutely necessary before implanting a neuroprosthesis. as there is no other
way of predicting success. . -,-..,.
With an implanted neuromodulation system 19 of 23 patients, refractory to all other treatments, were
improved by al least 60%. One primary lailure was seen and 2 recurrences. Of course the follow-up
is relatively short so some more recurrences may be expected in this very difficult to treat patient
group. The recurrences could not be explained, as the stimulation response at the pelvic floor was still
present. Perhaps the pathologic impulses, at first overruled by the neuromodulating impulse, were
becoming even stronger than before. One patient suffered from technical problems, necessitating
several re-operations, but neuromodulation still seems to be effective.
The materials used in this first group o! patients were not especially designed for sacral neuromodu-
lation. With the development ol new equipment, even better results with less complications may be
expi'i ied. ...,:.
Conclusion Nruromodulalion of the sacral nerves, by means of an implantable pulse generator and
foramen electrode, is a promising new treatment for patients with otherwise untreatable voiding dys-
functions. A percutaneous test should be done on patients selected for implantation. Before turning to
irreversible, organ-damaging surgery like ileocystoplasty or urinary diversion, neuromodulation
should be considered.
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Ncuromoiiululion is advocated as a new treatment modality for urinary urge/frequency, urge-inconti-
nence, and some forms of urinary retention for those patients who are refractory to all other treatment
modalities, such as medication, pelvic floor excercises, bioleedback, and bladder dilation (1-5). The
method was originally developed by Schmidt and Tanagho (1) as a spinoff from their studies on neu-
rostiinulation in patients with spinal cord lesions. In neuromodulation, the entire innervation system
should be intact. The procedure consists of placing an electrode in one of the sacral foramina as close
to the pelvic plexus and pudendal nerve as possible and connecting this with a subcutaneous neuro-
stimulator. One ol the advantageous aspects of this treatment is that the expected success of the final
implant can be tested beforehand by a percutaneous nerve evaluation (PNK) test. However, one ol the
disadvantages is that the reported success rates on the PNlv testing average from 24% to 75%.
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Although these patients are called nonresponders. the real reason Tor their nonresponse often might
be a technical failure, meaning that there is dislodgment of the testing wire from the original position
close to the sacral branches of the pelvic plexus or pudendal nerve. Quite often it is scon on an x-ray
that the wire is lying out of the foramen after 1 or 2 days.
The aim of the study was to investigate whether we could improve our testing results in those- patients
who had a good acute PNE test but a technical failure in the chronic part of the test. We planned on
performing a two-stage implant, whereby only the electrode would be implanted in the first stage and
be connected to a temporary stimulator.
Material and methods In the present technique, neuromodulation treatment consists ol two parts:
(1) Acute/chronic PNK with an external stimulator.
(2) Implant of a permanent electrode (lead) connected to a subcutaneous neurostimulator (<>).
The PNE is divided into two separate episodes. In the acute phase, the patient is pul in a prone posi-
tion, with a pillow under the abdomen. A testing needle with isolation in the middle part -leaving the
first and last centimeter nonisolated- is introduced in one of the sacral foramina of S-2, S-3, or S-4.
The pelvic plexus and pudendal nerve run closely to the pelvic wall; therefore, the needle should just
enter the foramen. Stimulating the needle with an external stimulator will tell us if there is a good sen-
sory reaction (in the perineal area) and motoric action consisting of levator contraction, as seen by an
inpulling contraction of the anus. A concomitant contraction of the ipsilateral big toe indicates
whether we have stimulated S-3. The foramen of S-2 usually shows a rotation of the leg. S-4 does not
show any leg or toe movement. Because the optimal contraction of the levator is mostly seen in S-3,
this is the foramen most often used.
If the response at this acute test is adequate, a stimulation wire that is also isolated over most of its
length but leaves unisolated the last centimeter on both sides is introduced through the needle. II the
response of the wire is similar to that of the needle, the needle is removed. The wire is then anchored
to the skin with tape and connected to an external stimulator. The patient can now use the external
stimulator, changing the voltage himself or herself so that the sensory sensation is felt without pain.
The chronic phase consists of a period of 4 to 7 days in which the patient wears the wire and the
external stimulator, keeping a micturition diary. After the wire is removed, the pretest, test, and post-
test diaries are compared. To prevent psychogenic influences, a third diary is kept lor another week
after the test, in which a return to the baseline diary should be seen.
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Patltnti
Teiti
Patltntt
Implant!
Rejected
PNE tcore
99
174
52
47
52%
KIV m i • p«rtut*n*out n»rv« «vdiMtion
Currently. I lie criteria used tor an implant ol the permanent neurostimulator are as follows: A patient
showing improvement of more than 60% overall of symptoms (either correcting the frequency, the
number of pads, or ihe volume of urine voided) is called a responded and he or she is a candidate for
a pcrmaiu'til electrode implanted in the same foramen, now connected with a subcutaneous permanent
neurostimulator.
In our clinic, we also had an average success of 52% on our PNE tests (Table I). We were convinced
thai for patients having an insufficient result of PNE. the positive success score would improve with
a boiler testing method. The best electrode available is the permanent electrode used for the implant
because this wire is fixed to the sacrum by fixation sutures; however, this would mean an operation to
test the patient. Instead of waiting for improved hardware for the PNE, we decided to test our hypo-
thesis thai better selection is possible between nonresponders and technical failures by implanting a
permanent electrode as a testing method. This was performed in those patients who failed on the pre-
sent PNE lest criteria, but whose success might be anticipated because of good objective parameters
in the acute phase of the testing.
Of -47 patients who failed the chronic PNE test, 10 patients were carefully selected for the rwo-stage
procedure. When we had a total of 26 failed PNE tests, we analyzed the data. When using the crite-
rion of greater than 60% improvement oxer their pretest diaries during the chronic test, 15 had had
an initial good response the first hours or days and then failed. Obviously, the electrode must have
moved during that period. The other 10 had a good sensory feeling during the entire jx'riod. but «lid not
show an improvement in their micturition behavior. These were the nonresponders.
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We then decided to do a prospective study of the two-stage implant; the theory was that the perma-
nent electrode currently used is the only really stable electrode available. Patients who tailed two
chronic PNEs but who had a good initial response would be included. Of the next 22 patients who
were not considered for permanent implant. 15 patients fulfilled this criterion. Some patients expe-
rienced immediate loss of sensation after moving from the table. All patients had a second PNK after
the first failed. After the second PNE using the foramen that showed the best result, a two-stage
implant was considered. Five patients lost their confidence and did not agree to the two-stage implant.
Ten patients signed an informed consent.
In these 10 patients, the initial indications for neuromodulation were urge-incontinence (-1 patients),
retention (4 patients), and urgency/frequency (2 patients). The average age was «16 years (.32 to 66),
and there were eight women and two men. The average incontinence period was 3.6 years. All had
undergone all possible treatments: for urgency/frequency and urge-incontinence, mostly anlicholiner-
g\CV, fov «\\x«d mTOMm^W, SAlspelnSVön procedures in 5 parents; and Vor retention, prostate resection
(2 patients), suprapubic catheter (1 patient), and intermittent catheterization (1 patient).
It is known that especially obese patients have a problem of movement of the electrode. In some cen-
ters, obesity is considered a contraindication. In our series, 5 patients were overweight and ft were of
normal weight.
A two-stage procedure consisted of the following procedures: the permanent PICK-QUAD electrode
(Medtronic) was implanted in the best sacral foramen as was seen during the testing on the operating
table, using a median incision over the sacrum. The lead was brought to the ipsilateral side, where a
small additional incision was made. At that point, an extension wire was connected. This wire was
brought subcutaneously to the contralateral side and left the skin through a second small incision. The
extension wire was connected to an external stimulator (Fig. I).
The transposition to the contralateral side was chosen to prevent infection. With a long subcutaneous
tunnel, this danger was brought to a minimum.
In the next 5 to 7 days, patients filled in their diary as usual. Some went home and others stayed in
the hospital as ambulant patients if they lived too far away. If the micturition diary showed more than
a 50% improvement, the subcutaneous implant of the stimulator was performed in a second stage. The
second stage followed 5 to 14 days after the first stage. During this procedure, the extension wire was
removed and the permanent stimulator implanted subcutaneously (Fig. 2).
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Results During I he chronic testing phase with the external stimulator, 8 of 10 patients had an impro-
veincnl of more than 50% in their micturition diaries. Two of the 4 patients with retention had their
micturition restored to normal, 1 patient had an average residue of 50 mL, and 1 patient had no chan-
ge in retention. In the patients with urge-incontinence, the incontinence disappeared from 60% to
90%. One patient with urgency had a normal micturition frequency. Kight patients received the
impluntable stimulator (Itrel I I , Medtronic). After 6 months, pad use had diminished from 7.2 pads
per day at baseline to 0.4 at month 6 in the urge-incontinence group (Fig. 3).
Two patients failed to improve more than 50%. Of these 2 patients, one woman had had the electrode
implanted in S-4 but did not have a sensory response nor improvement in her micturition. Two months
later, she was retested per PNti; we found a proper acute response in S-3. The electrode was changed
horn S-4 to S-3, and she had 90% improvement of her incontinence during a second first stage. She
received the stimulator; this left only one failure (a patient with retention).
rhe iollow-up is 4 to 3(> months (average 16). No patients experienced infection because of the two stages.
cor-
Comment The hypothesis behind neuromodulation of the sacral roots (sensory and motor) is to c
reel, In the use of regulating electrical impulses, the dyssynergic activities of the cholinergic. adre-
nergic, and motor reflex pathways that initiate vesical storage and micturition (7). Although
some
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theories have been developed that explain the effects of neuromodulation, most of the results are baaed
on empiric findings in human studies (3). Some animal experiments and electrophysiologic studies in
humans show there is a spinal inhibitory action through the afferent branches ol the pelvic and pudi-n-
dal nerves (8). It is not clear whether neuromodulation primarily influences the micturition tenter
located near the thalamus. Others maintain that there is a direct correction ol the dyssynergia ol the
pelvic floor (pudendal nerve) by influencing the abnormal contractility ol the pelvic lloor. A normal
reflex pathway is induced, thereby decreasing bladder instability. Studies on the neurophysiologic
aspects of this regulation by electrical interference must still be initiated.
In our first series, we performed 174 PNE tests on 99 patients. In those patients where we were not
successful (less than 50% improvement), we repeated the procedure as often as four times. The aver-
age response is 52%. We believed it troublesome that, with the same parameters, it could not be pre-
dicted who would be a responder. So far, no predictive parameters could be found when looking at
urodvnamics, age, history, and sex (9). Some patients do have a successful acute testing on the table
and also sometimes during 1 or 2 days, but not enough for a permanent implant by our present stan-
dards. Especially obese patients have this problem, as do people who are very active. In some centers,
therefore, obesity is regarded as a contraindication for testing. In our view, those patients were not
nonresponders but technical failures. This is understandable when one realizes that there is a loose
67
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Wire in the foramen, passing a layer of subcutaneous fat that may move during walking, bending, or
Other activities. In addition, muscle contractions in active patients may dislodge the loose wire.
Tt may also be postulated that a testing period of 4 days is arbitrary. If the patient has a successful
acme testing, there is no reason why the patient should not respond to the permanent electrode unless
then- is an irreversible dyssynergic action between the pelvic floor and the detrusor. Especially in
patients with retention, urodynamics cannot exactly tell whether enough contractility in the detrusor
remains to restore normal micturition. In those patients, chronic testing is an absolute necessity. Some
authors argue that only the acute needle testing is necessary. However, because of the large cost of the
stimulator, most investigators want better proof ol predicting success by including the chronic testing.
It may be argued that this is also not an absolute proof, because the patient may influence (consciously
or unconsciously) the results by manipulating their micturition diary (for example, by recording lon-
ger intervals between micturitions or less loss of urine).
We wondered if 11,., results of .In- present PNK method could be improved with a more permanent
electrode in the foramen, I hereby preventing dislodgment of the test wire. Of course, the disadvanta-
ge is 1I...1 it involves an operative procedure as long as better testing wires are not available. Yet. we
were convinced that patients with proper parameters should not be refused modulation just because
of our present technical inabilities during the chronic testing phase.
In those patients who have successfully passed the PNK lest and received a permanent implant of
an internal pulse generator (IPG), the success rate ranges from 83% to 90% (3-4). In the patients with
mge-ineontinence. we found a 50% to 90% decrease in pad use or in incontinence episodes. The
patients with urgency/frequency also had a reduction of their frequency episodes by more than 50%.
In tin- retention group, there is an all-or-nothing effect, meaning that these patients achieve normal
micturition without residue in 85% of cases. In 15%. there was some residue, but an otherwise prac-
lu-rtlly normal micturition. None of these patients had to rely on self-catheterization anymore. It. the-
refore, shows thai 1 lu- permanent electrode, in combination with the neurostimulator. is a reliable treat-
ment form.
It should be assumed that the PNK test may include a larger percentage of success scores if more or
less the same material was used as in the permanent implantation.
In our two-stage series, patients were all in the group of the so-called nonresponders to the PNE test,
according to our present criteria, and were therefore excluded from permanent implant of an IPG.
I lowever, as they should be considered technical failures because the PNE technology at the present
txS
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stage is not ideal, we therefore chose to perform the two-stage procedure to improve the overall sue*
cess score for testing.
We have succeeded in eliminating the obvious technical failures in those patients who failed chronic
PNE tests and have subsequently improved our overall testing results.
In the past 5 years, many technical details in the hardware or software were improved: the testing
needles, the testing wire, the implanted electrode, and the stimulator have all been modified.
Obviously, there is room for further improvement in the technology.
In the future, Stifter testing wires may reduce the amount of technical failures. Until l inn, the two-
stage implant is an alternative in those patients with a proper acute PNE test and an indication of pro-
per response on the chronic test.
The selection of candidates for the two-stage implant should be made very carefully. First, repeated
PNEs should be tried. It is easier to repeat a PNE than to perform a surgical procedure, especially
when this procedure is meant as a test. There is no justification to go to a permanent implant a.s long as
temporary testing has not separated the nonresponders from the technical failures. The indication for
the two-stage implant is limited. The present study, however, shows that there is room for improvement
of the PNE electrode and simultaneous improvement of the results of neuromodulation as a whole.
Chapter 6
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CLINICAL RESULTS OF SACRAL NEUROMODULATION FOR CHRONIC VOIDING
DYSFUNCTION USING UNILATERAL SACRAL FORAMEN ELECTRODES f
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Chronic lower urinary tract dysfunction, such as motor urge incontinence, urgency-frequency syndro-
me pelvic pain, aiul bladder evacuation problems are a challenging therapeutic problem. Most patients
are initially treated conservatively with bladder retraining, pelvic floor exercises, and bioleedback. In the
majority ol cases this regimen is supplemented with anticholinergic drugs. However, about 40% of these
patients do not achieve an acceptable condition and remain a therapeutic problem.
Alternative procedures with variable success rates such as bladder transection, transvesical phenol injec-
tion ol the pelvic plexus, augmentation cystoplasty. and even urinary diversion are being advocated.
Neuromodulation is a new treatment modality based on stimulation of the sacral nerves. The postula-
tion is that by the induction of rhythmic contractions of the pelvic floor through the nervous puden-
dus a more coordinated micturition occurs through reflex pathways. This method was empirically
developed in the 1980s (11,16). Since then, several reports have been published on the use of neuro-
modulation in the treatment of voiding dysfunction (2.3,4.6, H. 18-20).
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Mexon .30 pacewire or temporary percutaneous lead (Medtronic, model 0-41830), which is connected
to the external stimulator. Alter wound dressing and securing of the lead with tape the patients return
to their homes. Stimulation parameters were as follows: unipolar monophasic, rectangular pulses,
pulse width 210 ms, pulse rate 15 pps, and amplitude 0.5-5 V. If an improvement of more than 50%
was seen in the main symptoms the test was called successful and the patient was selected as a candi-
date for implantation.
Implantation was done as described elsewhere (14). The complete device consisted of a foramen elec-
trode (IMCK-QUAl), Medtronic, model 3886 or 3080) connected to a subcutaneously implantable
pulse generator (II'G) via a lead extension (extension cable model 7495, Medtronic). In the first 15
patient!« an Itrel I IPG (Medtronic number 7421) was used, which enables telemetric resetting of the
stimulation parameters only at the fixed contact point on the electrode (unipolar). In the rest of the
patients an 11 re I II I I'd (Medtronic number 7424) was implanted, which enables telemetric switching
between the lour contact points (uni- and bipolar). Stimulation parameters were as follows: unipolar
mono phasic, rectangular pulses, pulse width 210 ms, pulse rate 15 pps, and amplitude 0.5-4 V.
Stimulation was either continuous or cyclic and daily use varied from a few hours to 24 h. The crite-
ria for success were as follows: good if the improvement in baseline symptoms was >90%, partial if it
was ^50% and <9()%, and poor if it was <50%.
The chi-squurc test was used to study the association between qualitative variables. Fisher's correction
was used when needed. The mean values recorded for symptoms and urodynamic parameters were
compared using the Wilcoxon nonpaiametric test. The Kaplan-Meier product-limit estimate was used
to calculate the median duration of the therapeutic effect of neuromodulation. The Breslow test was
use«! for comparisons between groups. As a final event we considered the loss of therapeutic effect or
the necessity lor removal of the implant. A 5% level of statistical significance was used for all analyses.
Results Alter being screenetl with the PNK test, 36 patients were candidates for a permanent implant.
All these patients were previously considered urological cripples, in whom no treatment other than
urinary diversion could be considered. This series consisted of 27 women (75%) and 9 men (25%) of
ages ranging from 23 to 67 (median 45) years. Overall, 24 patients (66%) complained of urge incon-
tinence: 6 (17%), of urgency-frequency syndrome: and 6 (17%), of nonobstructive urinary retention.
In addition, 16 patients (44.4%) felt perineal, hypogastric, or scrotal pain in association with their voi-
ding complaints.
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The median duration of complaints of voiding dysfunction was 6 years. In all. 30 (86%) ol the patients
had tailed to respond to chronic oral medication. Anticholinergics won- tin- drugs most frequently
used (80%), but alpha-adrenergic agonists and antagonists, analgesics, tricyclic antidepressanUs, nuis-
culotropic relaxants. desmopresin, and antibiotics were also used alone or in combination with anti-
cholinergics. Of the total patient group, 16 (-4-4.4'H») had a previous history of at leasl one operation on
their lower urinary tract (Table 1). At the first visit, 8 patients used intermittent sell-ialheleri/.ation
(median 4 times a day), 1 patient had a permanent urethral catheter, 2 had a permanent suprupuhic
Table 1 AM/ <//>/YV<<>/A< .'«/ycry /// /><;//«•/»/.' <-<w,>iWmJ /<»
Type of operaf»on
Lower urinary tract surgery:
Urethrosuspension
Urethral dilatation
Bladder neck incision
Blind urethrotomy
Transurethral resection of the prostate
Teflon injection
Artificial sphincter
Clam ileocystoplasty
Pelvic surgery:
Histerectomy
Herniorraphy
Ureter reimplantation
Epididymectomy
Oopherectomy
Uteropexy
Anus dilatation
Pelvic abscess secondary to Stamey procedure
Rectal amputation
Other:
Laminectomy LI—S4
(a) Operations are not mutually exclusive
/Vi/mber |
Table 2. /•'//»(»/ I <>/'MfM/wif<>«W<f//<>/i
12
4
7
3
3
1
1
4
15
4
1
3
1
1
1
1
1
Outcome
Good
Partial(a)
Failed:
No effect
Explanted
n (%J
17(47.2)
3 ( 8.4)
4(11.1)
12(33.3)
7.S
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Table 3. / , , „
,,/,/W ; ,W.,,
/mber /n/t/a/j * g « Sex Vo/d/r>g
(years,) dyjf'uncf/ort
qroi/p
W 60 M Urge incontinence
MS <?5 F Urge incontinence
34 F Urge Incontinence I
deWce
1
1
Pw/od or
fo//ow-up
Cmonfr»)
36
24
Psycbo/og/ca/
background
Hypermotilitysyndrome, stroke
Psychosocial problems, IPG
aversion
Outcome:
trterapeut/c
effect
Lost
Lost
Treatment
Explanted
Explanted
further
management
No
No
HP
«
R
R
LR
39
56
39
39
66
34
42
F
F
F
M
M
F
M
F
F
U l ( | C I l l l . M M , , I , - , 1 . V
Urirnry retention
Urge Incontinence
Urge-frequency
syndrome
Urge Incontinence
Urge incontinence
Urge-frequenty
syndrome
Urge incontinence
Urge incontinence
31 M Urinairy retention
36 Persistent pain at implant site,
IPG aversion
12
Lost Explanted No
10
6
3
24
36
12
12
2
2
Normal
Sexual trauma, incest, suicide
attempts
Sexual abuse
Psychogenic erectile dysfunction,
psychosomatic problems
Lost to follow-up
Incest
Anaphabet, several psychosomatic
diseases
Sexual abuse
Hypermotility syndrome,
primary enuresis
Lost
No
No
Lost
Lost
Lost
Lost
No
No
Explanted
IPG still in place
Explanted
IPG stillin place
IPG stillin place
Explanted
Explanted
Explanted
IPG stillin place
lleocystplasty
No
No
No
No
No
Bladder
denervation
No
No
Normal
BV
P
N
48
58
44
F
F
M
Urinary retention
Urge incontinence
. Urge-frequency
syndrome
M
II
II
36
6
12
Normal
Normal
IPG aversion
Lost
Lost
No
Lost
Explanted
Explanted
Explanted
Explanted
Cystectomy,
Indiana
pouch
No
Indiana pouch
No
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catheter, 20 used diapers daily (median 6 pads a day). 2 were on biofeedback treatment, and 7 wore
undergoing physiotherapy of their pelvic floor muscles.
The final results, recorded after an average follow-up period of 37.8 months (range 12-60 months)
according to the predefined criteria, are shown in Table 2. Altogether, 19 patients (62.8%) remain in
close follow-up at 5years after the implantation. In two of them the result was considered partial. One
patient (2.7%) was known to have a partial improvement prior to being lost to follow-up because of
death not related to neuromodulation treatment. In 16 patients (44.4%) the result was insufficient
because neuromodulation lost its effect or the implant had to be removed. Table 3 shows a summary
of the evolution of this group of patients. In all, 12 of these patients (75%) had some kind of previous
psychological disorder. Five patients never showed a good response after ilu- implantation. Although
they had an excellent result when the PNK test was done, a stimulation response could not be repro-
duced and, after a short period, the result was considered poor.
Altogether, 1 1 patients had a secondary loss of therapeutic effect after a median period of 17 months
(range 4-36 months). Re-operations had to be done in 12 patients to remove the I PC due to a secon-
dary loss of therapeutic effect and/or to a lack of satisfaction regarding the implant; alterward, major
surgery was performed in 3 of them as treatment for the primary voiding dysfunction. In the rest of
the patients, no further treatment was considered. Indeed, four patients currently have the stimulator
in place without any therapeutic effect.
The influence of neuromodulation on symptomatology and urodynamic parameters is presented in
Tables 4-6. Statistical analysis for the comparison of values obtained at baseline and at 6 months after
implantation was done only in the group of patients complaining of urge incontinence. The sample size
of the other two groups, urge frequency (six patients) and nonobstructive urinary retention (six
patients), was too small to enable inferential testing.
In the group with urge incontinence, at 6 months after implantation a statistically significant impro-
vement in all symptoms except urgency was observed. The total volume voided increased signiflcant-
ly. Other positive side effects were found in 13 of the 16 patients with pain in combination with incon-
tinence. The pain was reducedor no longer present. Furthermore, among five patients with defecation
problems a normal defecation rhythm was achieved in three cases, with regard to urodynamic para-
meters, statistically significant increases in total bladder capacity and in volume at first sensation were
seen. The volume at the first unstable bladder contraction increased as well, but not enough to reach
statistical significance (P= 0.0581). The maximal detrusor pressure at unstable contraction and post-
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Outcome
Good Parf/a/
Median period
of therapeutic
er7ecf (b)
A> va/oe W
Stx:
F
M
Group:
Nonobstructlve retention
Urge Incontinence
Urgency-frequency syndrome
IPG device:
I
II
Previous psychological
disorders:
No
Yes
27
9
6
24
6
15
21
(75)
(25)
(17)
(66)
(17)
(42)
(58)
17
i
3
14
3
7
13
(82)
(18)
(18)
(64)
(18)
(35)
(65)
3
0
0
3
0
1
2
(100)
(0)
(0)
(100)
(0)
(33)
(67)
10
6
3
10
3
8
8
(42)
(38)
(19)
(42)
(19)
(50)
(50)
Not
24
24
Not
36
36
Not
reached
reached
reached
(d)
(d)
(d)
25 (69)
11 (31)
18 (94)
1 (6)
2(67)
1 (33)
7(44)
9(56)
Not reached (d)
(*) Pitltntt In whom nturomodulatlon lost IM lhtr»p»ulic eHect or tht IPG h»d 10 b« rtmovad
(b) P»tltnn with partial Improvement w t r t Included In th« group with good rnu ln
(c) Brtilow trvt
(<l) At ihr «nd ol th* follow up period. In more than SOS of the petients the therapeutic effect of neuromodulation remains
0.2747
0.9793
0.5359
0.008
void residual volume showed a slight decrease (Table 6). Nevertheless, in patients with urinary reten-
tion the average postvoid residual volume decreased from 217.7 to 57 ml, and in patients complaining
of urge and frequency syndrome the average volume at lust sensation increased from 102 to 221.7 ml.
The median duration of the therapeutic effect for the entire group was longer than 60 months (Fig. 1).
We could not demonstrate significant dilVerences in the median duration of therapeutic effect with
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Table 5. <>/"/»<7//v/MVw/rf//<>*i i»/» .ivm/>/<>/u.i //» <>/'/«< J / I«VIA< M/yi- /«<ivf//««7»ir <»//<•/•
/»aramefe/-
Frequency
Major leakage episodes
Minor leakage episodes
Pads used per day
Urgency
Volume voided
(a)WikOKOn nonp*r«m«trt< * • * '
ßase//ne
mean ± Sf M
13.7 ± 1.37
4.9 ± 1.44
5.1 ± 1.2
6.6± 1.1
3.1 ± 0.3
158.0 ±18.5
(After (6 months;
mean ± Sf M
8.7
1.1
1.3
2.3
3.1
2280
±2.6
±0.7
± 1.5
±0.9
±0.2
± 26 2 +
Mean
change
5
3.8
•3.8
-4.4
•0.83
70.5
P va/u« fa)
0.0063
0.0039
0.0111
0.0011
0.3911
0.0117
Table 6. /$<•<•/ <>/ /i<7//v//W«/d/<«>/i <>//
" / '«"• ' "" ' ' '« ' ' " • ' ' " '^«'.</''<"'/' < "'!'/'' /««v</i///irtnr <;//<r 6
L/roc/ynam/c parameter
Bladder capacity (ml)
Volume at first sensation (ml)
Volume at first unstable
contraction (ml)
Maximal detrusor pressure at
unstable contraction (cm H20)
Postvoid residual
(a) Wilcoxon nonparametrk test
Base//ne
mean
187 ±29.3
101 ± 24.3
114 ±78.7
56 ± 10.5
110 ± 57
After (6 months) Mean
mean ± SfM
273 ±31.3
194 ± 28.2
179 ±91
42 ± 12
66 ±41.5
change
+85
+92
+ 178
-15
44
P va/i/e 9 fa)
0.0108
0.0025
0.0581
0.3488
0.9164
regard to sex, the type of voiding dysfunction, or the IPG type (Table 4). However, the median dura-
tion of the therapeutic effect in patients with a previous history of psychological disorder was 12
months, whereas in 18 of 25 patients (72%) without these antecedents the effect lasted for more than
36 months (P= 0.008; Fig. 2).
Complications were mild, but 56 operations were needed. In all, 37 reoperations (66%) were perfor-
79
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mud on the group of patients in whom the therapeutic effect remains. The rest •were performed in
attempts to improve the success rate for the group of patients in whom permanent neuromodulation
had initially failed. The most frequent complication was lead problems (38%); the lead had to be repo-
•itioned 19 times because of loss of therapeutic effect, pain at the site of the lead, isolation damage,
and slippage. Complete replacement of the Ieadwas done three times, once because of a lead fracture
and twice because of a technical problem. The Itrel I IPG was replaced by either the Itrel II or the
Inlerstim IPG (Medtronic number 302.3) to make the stimulation program easier.
Four patients (12%) complained of pain at the site of the stimulator, which resolved after repositio-
ning of the stimulator away from the scar of the previous incision. The stimulator was definitely remo-
ved when the patient required it, in cases of aversion, or when it was considered that the treatment
had completely failed (Table 7).
Although the sample size is small, the tic ml ol the number of reoperations is interesting. In patients
Tnhlt* 7. Mwi>//.'/(>/• /vi'/'ivv;/((W
Opera f/on upon n (%,) fa)
Und:
Repositloned 19 (40)
Replaced 3 (5)
22 (38)
Stimulator:
Change Itrel I —> II
Change Itrel I — > III
Change program stimulation (Itrel I)
Repositioned
Explanted
Extension cable:
Rppl.icm)
(•) Any kind of tutgeiy is not mutually «xclusiv«
4
1
8
7
12
33
2
2
(9)
(2)
(14)
(12)
(21)
(58)
(2)
(2)
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without a previous history of" psychological disorder the number of reoperations remained stable.
However, in patients with a previous history of psychological disor der the number of reoperations
gradually decreased. This observation reflects our reluctance to reoperate on this group of patients
once the therapeutic effect of neuromodulation has been lost (Kig. 3).
Discussion The interaction between the autonomic and the somatic nervous system is an integral part
ol the neural control ofthe voiding mechanism as well as the stability of the bladder. Some of these
interacting reflexes are inhibitory, whereas others are facilitative. A perfect balance between them is
required for the accomplishment of normal voiding and the maintenance of bladder stability.
Dysfunctional voiding syndromes are associated with a degree of labile sacral reflex behavior. Therefore,
by making use ofthe interacting reflexes we can modulate pelvic floor and detrusor instability. The main
principles behind neuromodulation of voiding dysfunction and bladder instability are based on two fac-
tors: detrusor instability can be inhibited and pelvic floor and external sphincter instability can be con-
trolled through neural stimulation ofthe somatic fibers ofthe sacral roots (15).
Unilateral sacral segmental stimulation with a permanent electrode at the level the sacral foramen S3
or S4 can offer an alternative non-destructive treatment for patients with dysfunctional voiding syn-
dromes and chronic pelvic pain refractory to conservative measures.
Since 1989, when a clinical trial was started to evaluate the effectiveness of this new treatment moda-
lity, experience has been gathered with regard to evaluation, surgery, and follow-up ( I I ) . Indeed, alt-
hough there is no longer any doubt about the possible effectiveness of neuromodulation in the relief
of voiding symptoms, several points need further clarification before it can achieve the status of an
established treatment modality. We lack a complete explanation of its mode of action. Long-term fol-
low-up data and results from randomised studies to assess its efficacy properly are not available. The
reason for the discrepancy between symptomatic improvement and urodynamic findings remains un-
known. The mode of action of sacral neuromodulation remains unclear, but it has been hypothesised
that the electrical current modulates reflex pathways involved in the filling and evacuation phases of
the micturition cycle (17).
Stimulation of A-5 myelinated fibers of sacral roots S3 and S4 decreases the spastic behavior of the
pelvic floor and enhances the tone ofthe urethral sphincter. The threshold ofthe somatic component
ofthe spinal nerve that innervates the pelvic floor is lower than that of the autonomic component of
the bladder. Thus, simultaneous bladder contraction is avoided during stimulation. In many subjects
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primary voiding dysfunction appears to begin with unstable urethral activity, which activates the voi-
ding reflexes, leading to detrusor instability and associated urgency, frequency, and incontinence. The
inhibitory effect of the enhanced urethral sphincter tone suppresses detrusor instability and sta
bilises detrusor activity.
Bladder underactivity may be the result of an imbalance between excitatory and inhibitory reflex
mechanisms. In patients with chronic urinary retention the aim of stimulating S3 is to recover volun-
tary control of the pelvic floor musculature to initiate voiding (6,9). In the case of chronic pelvic pain,
neuromodulation lessens the perceived intensity ofthe pain by exciting antinociceplive neuronal sys-
tems and masking or changing the nature ofthe pain through the sensation of the electrical stimula-
tion (10).
It must be kept in mind that the therapeutic effectiveness ofthe stimulation is that of a modulatory in-
fluence on the reHexes controlling micturition and its related dysfunction. Similar parameters of sti-
mulation can be applied to seemingly paradoxical clinical problems, a urinary retention disorder as
well as one of urinary incontinence; both can be secondary to a dysfunction ofthe neural reflexes and,
as such, respond to the same modulation input to the CNS obtained from neurostimulation (12).
After subchronic stimulation about 13-62% of patients are possible candidates for definitive implan-
tation (5,7,8,11). We believe that this figure could be increased if we could overcome some technical
problems. We observed an early lead displacement in almost 20% of patients showing normal S3
responses when screened by PNE. This is an outpatient test. In some patients the resistance of the
lead against displacement is insufficient. For this reason we have started to test a new lead designed
to increase resistance against displacement. According to previous reports, about 25% ol the patients
who respond well to a percutaneous trial fail to respond to a permanent implant (8,1 1,13,18,19). In
our study. 7% ofthe patients never had a good response after the implantation.
The data suggest that one could improve the results if more stringent screening were undertaken. A
patient should not be offered permanent implantation unless there has been a significant improvement
of symptoms during the subchronic test. In an attempt to decrease this high number of failures a logis-
tic regression analysis has been carried out to determine predictive factors of success in neuromodu-
lation (9). As explanatory variables the investigators used clinical and urodynamic parameters, but,
unfortunately, none of these provided enough significant independent information to predict success.
Different approaches have been used to make implant decisions more reliable.
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More llum DUO sulichrunic test i;m In- undertaken it there is any doubt or reluctance on the part of the
patient or if there is any doubt as to the technical success achieved in the initial outpatient trial. A two-
stage procedure has been proposed as well as a longer test stimulation using urodvnamics as an objec-
tive measure of improvement (5,7). In those patients who fail to achieve relief with a permanent
implant, the lack of maintaining an efficient contact with the nerve could be the explanation.
The high numbers of operations undertaken to reposition the lead in patients in whom the therapeu-
tic effect persists reaffirm this assumption (up to five repositions ol the lead being done in a single
patient). Special attention is needed with regard to patients with a previous history of psychological
dysfunction and/or sexual abuse, l'urthermore, it is noteworthy that aJl these patients had a good
response to temporary stimulation and their symptoms returned to baseline thereafter. Our data indi-
cate that 82% of these patients showed poor results as compared with 28% of the patients without a
history of psychological disorders (P=0.002).
Moreover, 25% ol all reoperations were done in patients with psychological disorders. In most of these
patients the reoperations had no effect. Since we had our doubts about the effectiveness ot reoperations
in this group, the number decreased slightly during this study (Fig. 3). In our experience this group of
patients is hard to deal with, ami it is extremely important that one be alert so as to identity them.
Data about the psychological kukground of the patients were obtained alter a thorough and careful inves-
tigation (Table 6). At the time ol the initial contact, most of the patients were reluctant or refused to talk
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about former traumatic events that could explain or influence their present behavior. Some of these datu
were obtained from their general practitioners since it was impossible to get them directly from the patients.
In the future a more restricted indication for a permanent implant must IH> adopted. Psychological tests or
psychiatric evaluation at the beginning of the study may help to identify these patients.
Permanent electrode stimulation obtained a 52.8% efficacy rate among a group of patients who, by
definition, were refractory to all presently available conservative forms of treatment. This percentage
is in the same range as that reported previously (M, 17), although success rates of up to 8.3% have been
published (2,3,1 1). When the voiding groups are taken into consideration separately, our success rate
is slightly lower than those reported before. Klabbady and colleagues H) obtained practically a 100%
success rate in both patients with urinary retention and patients complaining ol pain, frequency,
and/or urge incontinence.
In a homogeneous group of patients with urge incontinence due to bladder instability, llosch ;nnl
Groen (2) obtained an 83% success rate, and Vapnek and Schmidt (1')) achieved an 85% rale in
patients with urinary retention. However, our results were influenced by several decisive factors.
First, the patients belonged to an indication finding study done during the first period ol our learning
phase (1991-1993). Second, psychological disorders were found a posteriori in 30% of the patients,
which clearly influenced our final results. Finally, the patients selected for permanent implantation
had undergone 64 different kinds of operations in the pelvic region, which caused concomitant disor-
ders of the lower urinary tract that were not cured by neuro-modulation. Nevertheless, the therapeu-
tic effect of neuromodulation remains present in the majority of patients as evidenced by the long-term
follow-up. Although the average period of follow-up was 37.8 months, 52.8% of the patients continue
to benefit from the neuromodulation effect after 5 years of follow-up.
Furthermore, the median duration of the neuromodulation treatment effect for the entire population
was longer than 60 months, indicating that lasting symptomatic improvement is possible. On the other
hand, we realise that our study lacks a control arm. However, we noticed that when the stimulation
was decreased below a certain level or became too slight to be felt, the symptoms recurred. In 1993 a
new randomised multicenter study was initiated to compare neuromodulation with existing conserva-
tive treatment using a 6-month-delay arm (8).
The discrepancy between the symptomatic improvement and the urodynamic findings continues to
need an answer.
Some studies have been capable of measuring the neuromodulation effect objectively by the perfor-
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mance of urodynamics studies dur ing temporary st imulat ion (5,18), whereas others have not found a
complete correlat ion (2,6). Ambula tory urodynamic investigation can help us to understand better the
neuromodulat ion effect on lower ur inary tract funct ion. However, var iabi l i ty is inherent in all urody-
namics studies ami renders the reproducib i l i ty d i f f icul t (2) . «»:;-' ^ ? i >: >. / .•.;
Th r number ol re-operations was higher than those reported previously. However, this figure was inf-
luenced by two lactors. In the i t re l I group, each change to another st imulat ing point required a reope-
ration lining local anaesthesia (8 times, 14%), and our first implanted patient needed 12 re-operations
to overcome various kinds ol technical problems. Indeed, most re-operations were performed becau-
se ol technical failures (Table 7). Revisions per lormed because of loss o f st imulat ion or deter iorat ion
of response were also common, but the major i ty o f these occurred because o f poor selection cr i ter ia.
In conclusion, on I lie- basis o f the results we obtained using neuromodulat ion and a long period o f fo l -
low-up, it is evident that the therapeutic benefit is a result of the modulat ion o f neural reflex excita-
bi l i ty rather than ol a direct change in muscle behavior or in the integr i ty o f neural conduct ion. The
effect is immediate and voluntary muscle contract ion is not inhibi ted by the st imulat ion. A l though
results I m m randomised studies are not available, enough informat ion has been gathered for neuro-
modulat ion to be considered an effective treatment modal i ty in patients w i th severe vo id ing dysfunc-
t ion. Since historic studies were done in not-wel l-def ined groups of patients and since there have been
considerable advances in I hi» development of neuromodulat ion devices, a higher success rate may be
achieved in the future.
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Introduction Urinary urge incontinence denotes a condition in which a sudden strong urge to urina-
te is followed by an involuntary loss of urine. Urge incontinence, which aftects women and the elder-
ly disproportionately, is disconcerting to patients, adversely affecting their quality ol lite-, and imposes
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substantial economic costs (1). The condition is classified as detrusor hvperrelle.xia in the presence of
a precipitating neurologic abnormality and detrusor instability in its absence (2). Neither tlu> epide-
miology' nor the pathophysiology of urge incontinence has been well delineated, though available evi-
dence suggests that subclinical neurologic disease or primary smooth muscle disease may contribute
to the disorder in some patients (I). ^
Currently, urge incontinence is typically managed conservatively by behavioral techniques auch U
bioleedback, bladder retraining or pelvic muscle exercises: pharmacothcrapy involving anticholiner-
gic, antispasmodic. or tricyclic antidepressant medications; and dietary modification. These appro-
aches tail to yield satislactory outcomes in an estimated 40% ot patients. In those refractory urge
incontinence cases invasive procedural interventions such as intravesiculur inxtillatinnN of cupsaicin,
bladder transsection, transvesical phenol injection ot the pelvic plexus, augmentation ileocystoplattty
and even urinary diversion have been advocated, although comparatively high rail's of incontinence
recurrence as well as of complications limit the appeal of these procedures.
Sacral root neuromodulation using an implantable pulse generator (1PG) has emerged in recent years
as an attractive therapeutic alternative tor patients with refractory urge incontinence, as well as cer-
tain other forms of refractory voiding dysfunction (3,4). Neuromodulation is less invasive than avai-
lable surgical procedures, preserves the anatomical integrity of the lower urinary tract, and can be
readily reversed. Rates of response to neuromodulation in the 52-8.3 % range have been reported
among urge incontinence patients (5-8). Patients with urgency-frequency syndrome as well as urina-
ry retention have also been found to benefit (7,9-12). The effects of neuromodulation have thus far not
been found to diminish with chronic use (13). Nor has neuromodulation been associated with any
reported cases of permanent adverse change in perineal sensation or micturition behavior or of nerve
injury. The mechanism of action of neuromodulation is not well understood; nevertheless, neuromo-
dulation-induced alteration in the activity of reflex pathways involved in the filling and evacuation
phase of the micturition cycle has been postulated.
Studies of neuromodulation to date have involved comparatively small numbers of patients, limited
periods of follow-up, and non-randomized designs. The present report presents the results of the first
randomized comparison of sacral root neuromodulation with conservative management in patients
with refractory urge incontinence. This controlled clinical trial involved a larger number of patients
than that in any previously reported study, and patients were followed for up to 36 months after com-
mencement of neuromodulation.
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Fig. 1. Study design
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Material and Methods This prospective randomized clinical trial was conducted at the University
Hospital Maastricht, Maastricht, The Netherlands and the University Hospital St. Radboud,
Nijmegen, The Netherlands. During the period From December 1992 through January 1997, 123 con-
secutive patients with refractory voiding dysfunction rendered their informed written consent to
undergo evaluation as potential study participants, including percutaneous nerve evaluation (PNE).
Refractory voiding dysfunction included any of the following conditions that had proven unresponsi-
ve to standard currently available treatments: (a) urge incontinence; (b) urinary retention or voiding
dysfunctions, such as hesitancy or inlermittency. due to an acontractile detrusor or obstruction due to
urelhral overactivity; or (c) severe or protracted urgency/frequency syndromes in the absence of
incontinence. Although only the urge incontinence patients were the subject of the present study, the
patients with the other types of refractory voiding dysfunction were also potential candidates for neur-
omodulation and therefore also underwent PNE.
The design of the study is depicted in Fig. I. Patient selection criteria included: age > 16 y; normal
upper urinary tract function, muscular and sensory responsiveness as demonstrated by PNE; detrus-
or storage capacity : 100 ml.; and absence of sphincter pathology. Patients were excluded on the basis
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Fig 2. Patient disposition
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of: stress incontinence; multiple sclerosis; Reiter=s syndrome; severe or uncontrolled diabetes or dia-
betes with peripheral nerve involvement; pregnancy; anatomical features that would preclude succes-
sful placement of an IPG; concomitant medical conditions limiting the prospects for successful neur-
omodulation such as spinal cord injury or cerebrovascular accident within the preceding (> months
period, active degenerative disc disease, or bleeding complications; moderate to severe ureteral reflux
or moderate to severe hydronephrosis; symptomatic urinary tract infection; and pelvic- pain of un-
known etiology.
Patient Evaluation Patients' general and urological history was documented, and physical examina-
tion, urinalysis, including cytology, uroflowmetry and urodynamic evaluation were performed.
Patients completed a voiding diary as well as an SF-36 quality of life questionnaire (14). The voiding
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Table 1 . /<*/.»<•////«* /'<///<•/
Parameter Conf/T>/ Group /mp/anf Group
Ottxter
Ftmalt 21
Male 2
Body weight
< 80 kg 19
H O kg 4
Detrusor function
Unstable 17
Stable 6
Number of PNEs
1 17
>1 6
Prior disorders
Musculoskeletal (a) 5
Neurological (b) 6
Psychiatric (c) 2
General gynecologic (d) 12
Gastrointestinal (e) 9
Recurrent urinary tract infection 9
91.3
8.7
826
17.4
73.9
26.1
73.9
26.1
21.7
26.1
8.7
52.2
39.1
39.1
19
2
17
4
16
5
16
5
5
4
2
6
4
S
90.5
9.5
81.0
19.0
76.2
23.8
76.2
23.8
23.8
19.0
10.0
28.6
20.0
23.8
(a) Including chronic back pain, aiümmx, .HUIMU> ...ni U- „ i^
(b) Including herniated nurltui pulpotui, epllepiy. tenuon headache
and caipal tunnel »yndrome
(c) Including depwtlon and hypervtnlilatioi
(d) Including hysterectomy, n regular menm «mi rmiomvtncnn
(e) Including appendectomy, obMipation. fecal Incontinence, polypectomy and anal fiuure
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diary data were used for determination of the three primary study outcome measures, viz, number of
leakage episodes per 24 h, leakage severity on a 0-3 scale, and usage of pads, including diapers, per
24 h. The leakage severity scale was: 0 for dry, 1 for loss of a few drops of urine, 2 lor loss of I -2 tables-
poons of urine and 3 for complete wetting.
Percutaneous Nerve Evaluation PNE, which consisted of an acute phase and a sub-chronic phase,
was performed as previously described (5,15). In the acute phase percutaneous electrical stimulation
was applied by the attending investigator to the ventral ramus at the level of the S3 foramen, or alter
natively S2 or S4, using insulated needles and an external, hand-held neurostimulator (Model 3(>25
Screener, Medtronic, Inc., Columbia Heights, Minnesota, USA). Patients exhibiting satisfactory
responsiveness proceeded to the subchronic phase, in which stimulation was applied via a temporary
percutaneous lead wire for a minimum of 72 h under patient control. Patients completed daily voiding
diaries during the sub-acute phase and again at least 72 h thereafter upon regression to baseline symp-
toms. Patients exhibiting ; 50% improvement in at least one of the three primary outcome measures
during PNE, upon granting their further informed written consent to undergo implantation, were
enrolled in the studv.
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improvement
d the control group in a 1:1
Chapter 8
Table 2. ( W i / y r>/7//<-
Parameter
Physical functioning
Physical role
Social functioning
Bodily pain
Mental health
Emotional role
Vitality
General health
Standardized physical
Standardized mental
Con fro/ Group
Sasefr'ne
Mean
569
59 1
52.6
57.6
71.1
786
61 0
590
38.4
47.6
95% O
46 1-67 7
48.4-69.8
48.9-56.3
46.2-69.0
61 9 80 4
688-88.4
50.2-71.8
507-67.3
34.6-42.3
43.1-52.1
6 months
Mean
51.1
589
54.9
54.6
67.0
77.0
56 3
560
36.7
46.3
95% O
388634
493684
49.6-60.2
45.1-64.1
57.7-762
67.4-86.6
46 1-66.5
47 1-65 0
32.7-40.8
41.1-51.5
/mp/artf
B«se//'rte
Mean
52.1
56.5
51.5
50.6
590
79.8
51.9
51.4
35.8
43.6
Croup
95% O
407-63.5
43 9-69.1
45.2-57.8
39 6 61.6
46.9-71.1
69 1-90.5
41 5-62 3
38.7 64.1
30.4-41 3
38.0-49.3
6 months
Mean
66.6+
59.8
53.8
59.0
68 8
89.81"
595
62.1
41.6*
47.3
95% C/
55.4-77.7
46.073.5
49 6-57.9
47.5-70.4
57 0-80.5
82.3-97.3
48.1-70.8
50.6-73.6
36.6-46.5
42.7-51.8
+p = 0.034 for within-group comparison vs baseline:
*p = 0.037 for between-group comparison vs control at 6 months
• p s 0.019 for within-group comparison vs baseline
phase of the study. Twenty-two of 23 control patients (9b%) underwent implantation at the conclu-
sion of the 6 months controlled phase.
Implantation IPG placement procedures were performed between «January 1994 and May 1997 by
previously described methods (10). Briefly, with the patient under general anesthesia, acute testing of
responsiveness was repeated after surgical exposure of the same sacral foramen previously succes-
sfully stimulated during PNE. The lead (Model 3886 PISCES-Quad Lead, Medtronic, Inc., Columbia
Heights, Minnesota, USA) was positioned and secured by fixation to the sacral periosteum or bone.
The IPG (Model 7424 ITREL7 I I Implantable Pulse Generator, Medtronic, Inc., Columbia Heights,
Minnesota, USA) was implanted in a lower abdominal pocket and connected to the lead by an exten-
sion (Model 7495 Extension, Medtronic, Inc., Columbia Heights, Minnesota, USA) threaded through
a subcutaneous tunnel. Stimulation wascommenced on the following day with initial pulse width of
210 (is, rate of 15 s-' , and amplitude of 0.1 V . Amplitude was thereafter increased in 0.1 V increments
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Table- 3. / '/Wy/#</////r /////<//<</;
/'»famefer ana 77/ne Po/nf
Bladder volume (mL)
First sensation
First contraction
Maximum fill
Oetruior preiture(cm H2O)
First sensation
First contraction
Maximum (ill
Pre/mp/anf
Mean
92.6
115.8
265.9
9.5
26.9
16.6
95% O
66.6 118.6
75.7-155.8
218.0-313.8
4.1-15.0
18.1-35.7
11.0-22.2
6 mofh Posf/mp/anf
Wean
167.2
370.2+
370.2*
6.6
32.5
13.8
95% O
59.2-275.2
324.9-415.4
324.9-415.4
2.3-10.8
15.4-49.6
6.9-20.8
M< • 0 IHHI'I vt pi«iinpUni *p • OOU vipr*lmpl*m
until sensory and/or muscularres ponses were evoked and then decreased by approximately 1 V. Sacral
root neuromodulation was the sole form of urge incontinence therapy administered during post-
implant follow-up.
Follow-up At the conclusion of the 6 months controlled phase of the study all patients completed voi-
ding diaries and quality of life questionnaires and were assessed by uroflowmetry and urodynamic tes-
ting. The same evaluation procedures were also followed by the control group 6 months after
crossover to implant. After evaluation at 6 months, post-implant stimulation was discontinued at least
72 h unlil regression to baseline symptoms, at which time patients completed additional daily voiding
diaries lor a 72 h period. At this juncture, stimulation was resumed, and a further diary was comple-
ted at least 72 h later when patient response to stimulation stabilized. Subsequent long-term follow-
up consisted in all patients ol completing voiding diaries at 6 months intervals.
Data Analysis Descriptive statistics were calculated and inferential statistical analyses performed
using SPSS 8.0 statistical software (SPSS, Inc.. Chicago, Illinois. USA). Mean values and 95% con-
fidence intervals (96% CD were calculated for parametric data. Inferential statistical tests were per-
formed on a two-tailed basis with an a level of 0.0 5. Between - groupcomparisons of nonparametric
baseline patient attributes were made by Fisher exact test. Within - and between - group comparisons
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Table 4.
Type Adverse Patients
fvents Affected
% (a) n % (b)
Pain at implant site
Lead migration
Leg pain
Leg stimulation
Bowel function disturbance
Urinary retention
Vaginal cramps
Anal pain
Skin irritation at implant site
16
8
7
2
2
1
1
1
1
42
21
18
S
i/i
3
3
3
3
12
7
7
2
2
1
1
1
1
29
17
17
S
',
^
2
2
2
(a) Percent of 39 total adverse events
(b) Percent of 42 implanted patients
of parametric results during the b months controlled phase of the study were conducted by Student's
test lor paired and grouped data, respectively. Percentage improvement at 6 months vs baseline was
calculated in cumulative decile increments (e.g., >40%, >50%, >60%, etc.), and between-group diffe-
rences in apportionment across cumulative deciles of improvement were evaluated by Mann-Whitney
U test. Post-crossover phase results from the implant and control groups were pooled. In the analysis
of the pooled results, baseline for the control group was defined to be the time point just prior to
implant, i.e., after the 6 months controlled phase. Within-group comparisons for post-crossover phase
data were conducted using repeated measures analysis of variance with simple contrasts or Student's
paired test. Nonparametric correlations between changes in primary study outcome measures and
those in urodynamic data were assessed by the Spearman rank method. The actuarial rate of treatment
failure was determined by the Kaplan-Meier product-limit method. For purposes of this analysis,
patients were declared to be failures at the time they (1) first failed to exhibit ; 50% improvement vs
baseline in at least one of the three primary outcome measures or (2) underwent IPG explantation.
Variables potentially predictive of treatment failure were evaluated by logistic regression.
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Results
Patient Attribute« The disposition of study patients is diagrammed in Fig. 2. Screening by PNE of
123 consecutive patients with refractory voiding dysfunction led to the enrollment of 44 patients with
refractory urge incontinence. More than one PNE was needed in 11/44 patients (25%), most often due
lo lead displacement subsequent to the acute phase of PNE. Ten of these patients underwent 2-3
PNEs, while one patient required five. The 56 patients excluded from study entry because of failure
to respond to PNE consisted of 21 (38%) with refractory urge incontinence and 35 (62%) with other
urgency/frequency syndromes without incontinence).
The median age of the enrolled patients was 43 y (range, 20-66 y) , and 9 1 % were female. These
patients presented with long-standing urge incontinence. The median duration of urge incontinence
symptoms prior lo enrollment was 9y (range, 2-34 y) . Twenty of the 44 patients (45%) had previously
undergone lower urinary tract or pelvic surgery, most frequently urethrosuspension to treat urinary
stress incontinence or hysterectomy. In loin- of these patients the possible contribution of urethrosus-
pension lo the development of urge incontinence had been documented.
The enrolled patients had received an array of prior treatments without satisfactory outcomes. Thirty-
six of 44 patients (82%) had received medication, most commonly anticholinergic or antispasmodic
agents, and prior treatment in hall the patients (22/44) had included use of more than one drug. Other
unsuccessful previous treatments included biofeedback, various forms of external electrical stimula-
tion, intermittent sell-catheterization, psychological counseling and denervation.
Upon randomization 23 patients were assigned to the control group and 21 to the implant group (Fig.
2). At baseline there were no statistically significant differences between the groups with respect to
any ol the three primary outcome measures (leakage episodes, leakage severity and pad usage) or to
an array ol other patient attributes (Table 1). Detrusor instability was not evident in 6 control group
and 5 implant group patients. In some or all these cases it is possible that ambulatory urodynamic eva-
luation might have revealed detrusor instability or that urge incontinence was due to urethral instabi-
lity. Neither possibility was investigated as part of the present study.
Controlled Phase Results One patient randomized to the implant group declined to undergo implan-
tation due to desire to initiate a pregnancy. The remaining 20 patients in this group received implants.
As shown in Fig. 3. at (> months mean leakage episodes (1.4: 95% Cl . 0.0-5.2) and pad usage (0.7; 95%
CI, 0.0-1.3) in the implant group had significantly declined (p < 0.0005) by 90% and 92%. respecti-
vely, compared with the respective baseline values of 13.5 (95% C l . 10.3-16.7) and 8.7 (95% CI . 5.8-
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11.6). Mean leakage severity at 6 months (1.6; 95% C l . 0.7-2.4) was also lower than thai at baseline
(2.1; 95% CI , 1.9-2.4) by 24%: however, this difference was not statistically significant. No significant
change from baseline in mean values of the three primary outcome measures was evident in the con-
trol group at 6 months. Mean leakage episodes, leakage severity and pad usage in the implant group
at 6 months were significantly lower by 88% (p < 0.0005). 24% (p - 0.047) and 90% (p < 0.0005).
respectively, than the respective control group mean values at 6 months of I 1.2 (95% Cl , 8.9-13.5).
2.1 (95% Cl . 1.9-2.4), and 6.8 (95% Cl . 5.2-8.5).
By 6 months significantly higher percentages of implant than control patients had achieved greater
percentage improvements in leakage episodes (p < 0.0005), leakage severity (p • 0.010) and pad usage
(p < 0.0005) vs baseline (Fig. 4). For instance, improvements in leakage episodes and p.ul u .>.r ol ;
90% were attained by 75% and 85% of the implant group, respectively, but none oi the control group.
Similarly, one third of implant patients achieved ; 50% improvement in leakage severity, while none ol
the control group did so. By b months 9/16 evaluable implant patients (56%) were completely dry, as
judged by pad usage of zero. Only one of the 22 control patients (4%) was dry at 6 months.
Implant patients, unlike their control group counterparts, exhibited significant improvement with
respect to two quality of life measures, as shown in Table 2. Thus, at 6 months mean physical lunc-
tioning score (66.6; 95% CI , 55.4-77.7) and standardized physical component scale (4 1.6; 95% Cl ,
36.6-46.5) in implant patients were greater by 28% (p = 0.034) and 16% (p = 0.019), respectively, than
the corresponding baseline mean values of 52.1 (95% Cl , 40.7-63.5) and 35.8 (95% CI, 30.4-41.3).
Additionally, mean score for role limitations due to emotional problems at 6 months in the implant
group (89.8; 95% CI . 82.3-97.3), though not significantly different from the baseline mean, was never-
theless significantly higher by 17% (p= 0.037) than the 6 months mean value for the control patients
(77.0; 95% CI , 67.4-86.6). No significant between-group differences were apparent at baseline in any
of the quality of life measures. Nor were any significant improvements demonstrable in the control
group at 6 months vs baseline. The absence in the implant group of significant improvement with
regard to a broader array of quality of life measures may be at least partly ascribable to the lack of dis-
ease specificity in the SF-36 health status scales used to evaluate quality of life (16).
At the conclusion of the controlled phase of the study, one control group patient elected not to pro-
ceed with implantation. This patient's decision was prompted by the need to undergo a neurosurgical
intervention for herniated nucleus pulposus.
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Pout-Crossover Phase Result« After neuromodulation for 6 months study patients underwent uro-
dynarnic evaluation (Table 3). At both first contraction and maximum fill mean bladder volume at 6
months« was significantly higher by 220% (p < 0.0005) and 39% (p = 0.013), respectively, compared
with the respective baseline mean». Mean values of bladder volume at first sensation and of detrusor
pressure were not significantly different at 6 months than at baseline. Changes at 6 months vs base-
line in mean bladder volume at maximum fill were weakly (r = 0.424) but significantly (p = 0.028) cor-
related with corresponding changes in leakage episodes. No other significant correlations could be
demonstrated between changes in urodynamic bladder volume parameters and those in any of the
three primary outcome measures.
At the conclusion of the 6 months period following implant the dependency of treatment effects on
uctive stimulation were evaluated by temporarily discontinuing and then resuming stimulation. As
indicated in I'ig. 5, upon discontinuation of stimulation a significant rebound was observed in mean
leakage episodes (p < ().()()()/>), leakage severity (p = (J.OOK) and pad usage (p < 0.0005) to levels com-
parable with those prior to implant. With the resumption of stimulation these three outcome measures
decreased significantly (p < 0.0005, p » 0.003 and p < 0.0005, respectively). Mean values of leakage
severity and pad usage after stimulation was resumed were not significantly different from those prior
to discontinuation ol stimulation. However, mean leakage episodes remained 33% higher (p = 0.031)
than the pre-discontinuation level.
The median duration of follow-up for the study patients was 18 months (range, 6-36 months). Over the
course ol follow-up 9 patients were declared to be treatment failures: 8 because of deterioration in the pri-
mary outcome measures and one due to explantation (I'ig. 6). The actuarial rate of treatment failure at 36
months was 32.4% (95% CI, 17.0-56.0 %). Among the non-failures mean leakage episodes, leakage sever-
ity and pad usage exhibited marked decline at 6 months post implant vs preimplant values and remained
stable at low levels throughout the duration of follow-up (Fig. 7). lx>gistic regression analysis failed to
reveal any significant predictors of treatment failure. Variables evaluated by logistic regression were: body
weight; number ol PNKs; detrusor instability: baseline leakage episodes: and history of muscular, neuro-
logical, general gynecologic or gastrointestinal disorders or of recurrent urinary tract infection.
Adverse Kvents Table 4 summarizes treatment-related adverse events. A total of 39 adverse events
were encountered in the 42 implanted patients. Twelve patients experienced a single adverse event,
while 8 patients experienced 2-3 adverse events, and 2 patients 4 adverse events. Most frequent was
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pain at the implant site, accounting Tor 42% of all treatment-related adverse events, followed by lead
migration (21%) and leg pain (18%). No intra- or perioperative complications accompanied tin«
implant procedure. Twenty-one post-implant surgical procedures were performed to resolve adverse
events, including 8 surgical revisions to correct lead migration and 8 to ameliorate pain at the implant
site. One patient accounted for 3 of the 8 procedures to relieve implant site pain, and (lu> final proce-
dure in this patient was 1PG explantatinn duo to intractable implant site pain.
Discussion The present investigation extends the available evidence supporting the efficacy and saf-
ety of neuromodulation for treatment of refractory urge incontinence and provided the finit randomi-
zed demonstration of superior outcomes with neuromodulation compared to conservative manage-
ment. At 6 months mean leakage episodes, leakage severity and pad usage were substantially and nig-
niheantly lower in implant than control patients, and significantly higher percentage improvements vs
baseline in all three primary outcome measures were observed in implant than control patients. Tin:
magnitude of improvement in leakage severity was lower than that in leakage episodes and pad usage.
It should however be remembered that, unlike the other two outcome parameters, leakage severity
was recorded on a non-linear scale and was subjectively assessed; hence, smaller improvement in leak-
age severity may be a reflection of the type of data recorded, although a relatively modest effect of
neuromodulation on detrusor contraction force could also at least partly account for this finding.
More than half of the implant group patients were completely dry after neuromodulation lor 6 mo.
Unlike their control group counterparts, implant patients also achieved significant improvement in
two quality of life measures. It is noteworthy that these results were achieved in a population of
patients with comparatively severe urge incontinence of long standing. Half the study patients expe-
rienced 10 or more daily leakage episodes at baseline and had endured symptoms of urge incontinen-
ce for nearly a decade or longer.
PNE, which assesses nerve root integrity and subjective response to stimulation, is essential in patient
selection for long-term neuromodulation. The rate of treatment failure during long-term follow-up in
the present study was comparatively low. Nevertheless, despite responding satisfactorily to stimula-
tion during PNE some recipients of permanent implants did not experience long-term benefit from
neuromodulation, for reasons that remain unclear. The explanation for treatment failure in many cases
may be technical problems in the delivery of electric stimulation to the target sacral nerves, for exam-
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pie, because of lead displacement (7). A novel distensible lead design currently under investigation
may offer one approach to reducing or eliminating treatment failure due to lead displacement. In other
cases the cause ol failure may reside in inappropriate patient selection. For instance, patients with psy-
chiatric disorder» may be at high risk of failure (7). Since only four of the patients participating in the
present study presented with a history of psychiatric disorder, it was not feasible to evaluate the role
ol this factor as an outcome predictor. Evaluation of an array of other baseline patient variables fail-
ed to reveal any significant outcome predictors, and this observation is consistent with the findings of
an earlier study (17).
In addition lo its superior effectiveness compared with conservative management as observed in the
I »resent study, ncuromodulation also otters the advantage of immediate onset of action, as well as
absence of systemic side effects. For instance, maximal effects of tolterodine and oxybutynin require
5-8 wk to develop f 18), and systemic side effects of pharmacotherapy can be treatment-limiting.
The present results serve to confirm earlier findings that neuromodulation is a safe therapy. Adverse
effects, most frequently pain at the implant site, were generally manageable, and the incidence of
serious complications was low. Only one patient required explantation. Nevertheless, the need for sur-
gical revisions is not infrequent and remains a significant limitation of neuromodulation in its current
form. Load displacement necessitating revisions could be more likely in obese or highly physically
active patients. As his been reported in earlier studies, no clinical evidence of nerve damage resulting
from ncuromodtilation was noted in the present investigation.
Major significant improvements in bladder volume upon first contraction and maximum fill were
documented during urodynamic evaluation at 6 months. Increases in urodvnamicallv assessed bladder
volume at maximum fill were weakly but significantly correlated with reduction in leakage episodes.
Nevertheless, no other correlations were apparent in urodynamic bladder volume parameters and the
three primary study outcome measures. The present observations of significant improvements in cer-
tain urodynamic parameters but limited correlations with symptom changes are consistent with those
of earlier neuromodulation studies (6.13). Plausibly, firmer correlations between subjective and objec-
tive parameters may emerge from the use of ambulatory urodynamic evaluation methods.
The effects of neuromodulation were found to be associated with continuing stimulation rather than
the presence of the IPG per se. Upon discontinuation of stimulation symptoms regressed to baseline
and thereafter improved again with resumption of stimulation. The prompt loss of symptom improve-
ment in cases of lead migration further underscores the importance of continuing stimulation. These
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observations affirm the reversibility of neuromodulation effects and also suggest that long-lasting and
significant alteration of muscular function or the integrity of endogenous neurotransmission resulting
from neuromodulation is unlikely.
The techniques and technology of neuromodulation continue to evolve (19). For instance, new lead
technology currently under clinical investigation holds promise for reducing the likelihood of lead dis-
placement, as well as enhancing the sensitivity of PNK. The potential utility of bilateral electrode
placement is also under investigation. Such technical advances may promote higher treatment success
rates and make the need for surgical revisions less frequent. Improved technology lor PNK may also
ultimately broaden the population of patients considered suitable candidates lor neuromodulation. In
the present study 25% of patients failed PNK and were thus excluded as candidates for neuromodu-
lation. A two-stage implant approach has recently indicated that .i nl. init ial proportion ol patients
failing conventional PNK may in fact be responsive to neuromodulation (I ' )) . While technical refine-
ments wil l likely improve further the results of neuromodulation in the 1'ulurc, this form of therapy is
already proving to be effective and well-tolerated in patients with refractory urinary urge incontinen-
ce, as well as certain other types of refractory voiding dysfunction.
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Introduction Sacud loot luuiromotlulatiun using an implantable pulse generator offers a well-tolerated
treatment choice tor patients with a variety of voiding dysfunctions that have failed to respond to more
conservative behavioral and pharmacological treatment approaches. A growing number of studies have
revealed that nouroinodulation can be effective in a high percentage of patients with refractory urge
incontinence, urgency/frequency syndrome and urinary retention (1-8). Rates of response to neuromo-
dulation have ranged from .V2% to 83% in urge incontinence patients who have exhausted other treat-
ment options (3,7,9). Neuromodulation is less invasive than available surgical procedures, preserves the
anatomical integrity of the lower urinary tract and can be readily reversed.
The high success rates of neuromodulation are to an important degree attributable to the identification
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of suitable candidates during a pre-implant percutaneous nerve evaluation (PNIi) procedure (10). I'NIv
entails the use of a temporary sacral foramen lead coupled to an external stimulator. PNK affords the
only predictor of success available to the clinician and is an integral part of neuromodulation therapy.
Fifty to sixty percent of candidates are usually judged to have responded sufficiently during PNI i
(>50% decrease in symptoms) to be considered for implantation.! 1-13 Failure to respond to the PNI i
stimulation test can be due to a number of factors. One known cause of unsatisfactory test stimulation
results is the migration of the test leads away from the optimal position for stimulation in the sacral
foramina. 11 In a standard PNE stimulation test, a lead with an electrode at its distal end is inserted
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and positioned by threading through a testing needle. Once the needle is removed, the lead is secured
to the skin with adhesive tape and then connected to the external stimulator. The unanchored elec-
trode end of the lead is vulnerable to migration resulting from movements in the tissue between skin
and bone. In a recent study 8 of 10 patients initially Tailing to achieve more than a 60% reduction in
symptoms during PNE with standard leads responded satisfactorily after substitution <>l leads that
were anchored to the sacrum with fixation sutures. ( I I )
Current PNE temporary screening leads embody a straight-wire design. Two novel test stimulation
leads with a coiled, pliable design have been developed. The present study evaluated in a goal model
system the ability of these novel designs to provide superior passive fixation compared with standard
leads. A comparison of the forces necessary for lead displacement and removal was also conducted.
Materials and methods
Animals Leads were evaluated in 8 female adult Dutch I^andrace goats of average weight 40 kg under
an experimental protocol approved by the Ethical Committee for Animal Experimentation <>l the
University of Maastricht, Maastricht, The Netherlands. Goats were housed individually in indoors
pens at 20 °C with a 12 hilight cycle and received food and water ad libitum. Goats were judged to
provide a suitable experimental model because of the similarity ol caprine and human sacral size and
anatomy .
Lead Designs The ability of three lead designs to apply s a cral nerve stimulation (SNS), resist migra-
tion and allow easy removal were compared: two novel coiled leads (Coiled Leads 1 and 2) obtained
from Medtronic Bakken Research Center, Maastricht, The Netherlands, and a standard PNE lead
(Model 041830, Medtronic, Inc., Minneapolis, M N , USA). The standard lead is an insulated straight-
strand wire design (FIG. l(a)). Coiled Leads 1 and 2 are composed of pliant insulated coilcd-strand
wire, differing only with respect to the distal electrode type: namely, ring-type (FIG. l(b)) and coil-
type (FIG. l (c)). respectively. Both coiled lead designs include a stylet in the center of the lead in
order to facilitate initial positioning of the lead in the foramen.
Lead Insertion and Stimulation Leads were inserted bilaterally in sacral foramina S2, S3 and S4, two
leads of each type per goat. In each goat, the standard PNE lead was inserted in the left S2 and S3
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foramina, Coiled I^ ead 1 in the right S2 and left S4 foramina, and Coiled Lead 2 in the right S3 and
S4 loraminu. For lead insertion and periodic monitoring of lead position by x-ray imaging, goats were
anesthetized with ()./> m l , of 20 mg/mL xylazine I M . At the end of the procedure xylazine anesthesia
was reversed by injecting ()./> mL of .5 mg/mL atipamezole hydrochloride I M .
A 9 cm long 20 gauge insulated needle (Model 041828, Medtronic, Inc.) was initially inserted in each
foramen lor acute stimulation testing. Electrical current was applied with an external test stimulator
(Model 3(>2f> Screener, Medtronic, Inc.) to the needle in increments until a visible muscle motor
response wax obtained. In goats, visible motor responses upon SNS are comprised of an upper leg
response lot* ioramen S2, an anal and tail response for S3 and primarily a tail response for S4.
Stimulation was applied at 15 Hz and a pulse width ot 210 us . A 1 cm vessel dilator was positioned
in the reel urn a.s a ground.
After HuccexNltil acute stimulation confirmed that the needles were properly positioned, the coiled and
standard leads were inserted intot the foramina through the needles. Each lead was initially tested
with the needle still in situ. Therealler, the needles and, in the case of the coiled leads, also the stylets,
were carelully removed so as to avoid lead displacement. The external sections of leads were attached
with adhesive tape to a cotton drape secured to the skin with sutures. The leads were then fully enclo-
sed in the cotton drape to protect them Irom damage during the post-insertion period of the study. A
lateral x-ray image was obtained to establish the initial positions of the leads in the foramina to a line-
ar precision of 0.1 cm.
Post-Insertion Follow-up Evaluations The inserted leads remained indwelling for 1,3.7 and 21 days
in 1,3,2 and 2 goals, respectively, and at each ol these time points threshold voltages to achieve reflex
motor responses at all indwelling leads were determined using the external test stimulator. After
induction of anesthesia but prior to lead removal, distance of lead migration was evaluated by x-ray
imaging and the force necessary to displace the leads measured by Chatil lon' Digital Force Gauge
(Model DI'XJS, AMETEK. Inc., l-argo. Florida. USA), larger displacement forces are indicative ol
greater potential resistance to migration. Thereafter, as the leads were being removed, the force neces-
sary for removal was also measured. Because in clinical PNE testing leads are intended solely for tem-
porary use, it is important that they be easily removable with minimal potential for tissue damage.
Smaller removal forces suggest comparative ease of lead removal.
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Data Analysis Data were analyzed using SPSS 9.0 statistical software (SPSS. Inc., Chicago, Illinois,
USA) and SigmaStat 2.03 (SPSS, Inc.). The significance of dilVerences in migration distance and
force ot lead displacement and removal was evaluated by Kruskal-Wallis one-way analysis ot varian-
ce on ranks with multiple pairwise comparisons using Tu key test- The relationship between migration
distance ot the standard lead and threshold response voltage was evaluated by linear regression.
Results
The study procedures were generally well-tolerated. No serious complications, infections or death»
occurred among the experimental animals, and all experimental determinations were completed u«
planned.
No statistically significant differences could be demonstrated in measurements ot lead migration,
threshold response voltage, displacement force or removal force as a function of lime over tin- siudy
tollow-up period of 1-21 d. Accordingly, measurements made at various study time points were pool-
ed tor analysis.
Lead Migrat ion As shown in FIG. 2, the standard PNE lead migrated in all 16 lest determinations
(median, 2.1 cm; range, 1.3-4.0 cm). In contrast, the median migration of both Coiled Lead I and
Coiled Lead 2 was zero. Migration was nil in 69% ol the determinations (1 1/16) for both coiled leads.
Moreover, when migration could be detected, it was minimal in magnitude, as revealed in FIG. 2.
Maximum migration was 0.8 cm for Coiled Lead 1 and 1.5 cm for Coiled I^ ead 2. The standard lead
migrated significantly farther than either of the coiled leads (p < 0.01). There was no significant dif-
ference in migration between the two coiled leads.
Threshold Response Voltage The TABLE summarizes the threshold response voltages measured
with each ot the three leads. With the standard lead up to 10.0 volts were needed to evoke a respon-
se, compared with 3.5 and 2.0 volts tor Coiled Leads 1 and 2, respectively. Nevertheless, the median
values were the same tor the three leads, and no statistically significant differences associated with
lead type were evident in threshold response voltages. As indicated above, the standard lead, but neit-
her coiled lead, was subject to frequent and substantial migration. As shown in FIG. 3, larger distan-
ces migrated by the standard lead were significantly linearly associated with higher threshold respon-
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»e voltages. This observation is consistent with the hypothesis that lead migration can result in lack of
ns|)(insf during PNIC. The data in FIG. 3 reveal that higher voltages were necessary to evoke a
response in cases of greater lead migration. However, 9/16 voltage measurements were made in cases
of Htamlurd lead migration £ 2.1 cm, and in these cases the median measured threshold voltage was
1.0 volt», likely accounting lor the lack of overall significant between-lead voltage difference as indi-
cated in the TABLE.
lat emcnt Force A» shown in FIG. 4(a), the standard lead was comparatively easily displaced. In
44% ol the determinations (7/16), displacement was observed at forces below the limit of detection.
The median force required lor displacement of the standard lead was 0.05 newton (range, 0.00-1.10
nowtons). In contrast, both Coiled la-ad I and Coiled Ix-ad 2 exhibited significantly greater resistan-
ce (p < 0.01) to displacement than did the standard lead, with median displacement forces of 0.80 new-
ton (range, 0.26-1.60 newtons) and 0.78 newton (range, 0.35-1.70 newtons), respectively. The two
coiled leads did not, however, differ significantly from each other in displacement force. The compa-
rutive difficulty ol displacing the coiled leads provides evidence of their capacity for passive fixation
and is consistent with I he observation that their migration from the initial insertion site was nil or
minimal.
Removal Force Significantly greater Force (p < 0.01) was required to remove the two coiled leads
compared with the standard lead, as indicated in FIG. 4(b). The removal force of the standard lead
(median 0.05 newton; range, 0.00-1.10 newtons) was in no case measurably different from the dis-
placement force. There was no statistically significant difference in removal force between Coiled
Load I (median 1.06 newtons; range 0.25-9.80 newtons) and Coiled Lead 2 (median 0.98 newton;
range, 0.35-1.86 newtons). However, removal forces were more variable for Coiled Lead 1 with the
ring-type electrode than Coiled Lead 2 with the coil-type electrode (FIG. 4(b)).
Discussion
Doth coiled leads evaluated in the present study exhibited a capacity for passive fixation significantly
superior to that of the standard lead. The number of leads that migrated anil the distance migrated were
both greater with the standard lead. Such lead migration can result in malpositioning of the distal elec-
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trode in relation to the spinal nerve, which could require retesting with its attendant expense ami
inconvenience or could result in false-negative PNK results depriving potentially responsive patients
of the benefits of neuromodulation.
Lead displacement from the optimal position for stimulation has been cited by clinical investigators as
a major reason for unsatisfactory PNK results. The electrode and lead have been obs«-r\ «-tI lo be com-
pletely displaced outside the foramen after 1-2 days of sub-chronic testing in some i , I M > ( I I ) . In a
recent multicenter clinical trial of sacral root neuromodulation tor the treatment ol urinary voiding
dysfunction involving more than bOO patients, (rank evidence ol lead movement during PNK a» reve-
aled by x-ray imaging was present in approximately 9% of patients.
In the present study a significant linear correlation was apparent between distance migrated by the
standard lead and loss of responsiveness to stimulation, as reflected by comparatively high measured
threshold response voltages. This finding provides further support for the conclusion that lead migra-
tion can contribute to inaccurate PNE results.
A third of the standard leads required stimulation at > 2 volts to achieve a response. Generally a peri-
neal muscle response in the range of 0.5-2.0 volts is preferred for clinical PNK testing (14). This vol-
tage range ensures an adequate space between the nerve and the electrode and minimizes pressure on
the nerve, maintaining patient comfort during stimulation. In the present study only a single coiled
lead required a threshold voltage > 2 volts.
Although the average time of sub-chronic testing is generally 3-5 days, temporary testing has been
reported over a period of weeks (15). With increased time, the possibility of displacement or local
fibrosis between the electrode and target nerve could be expected to increase. However, no significant
relationship between time of implantation and either displacement or threshold stimulation voltage
could be demonstrated in the present study.
The advantage of superior passive fixation afforded by the coiled lead designs needs to be considered
in light of the possible limitation of difficult removal after PNE testing or even unintended tissue
damage while attempting removal. The standard PNE lead requires very little force to remove: > 60%
of the standard leads required < 0.05 newton. Both coiled leads require significantly more force to
remove. However, the median removal force for these novel leads was less than I newton, and it ap-
pears unlikely that this magnitude of removal force would pose difficulties of clinical significance.
Nevertheless, Coiled Lead 1 appeared to be associated with greater variability in removal force nee-
ded and possibly greater potential for tissue damage or other complications. Consequently, Coiled
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Lead 2 appears to hold greater promise as a practical alternative to standard leads. >••••-• • •-'•.••:-
Another potential disadvantage of the coiled leads is that, because ot their pliancy, they cannot be
reposilioned once the stylet is removed. Moreover, after removal the stylet cannot be re-inserted into
the lead. Therefore, care must be taken to position the coiled leads precisely at the optimal site tor sti-
mulation and avoid displacing them during stimulation procedures. The relatively stiff standard leads
can I"- i < |'oniiioned to a limited extent in the foramen should the need arise.
Ollu-i ,i|>|>iout'hcs such as bilateral stimulation, tunneled temporary leads or surgical implantation of
the lead used in chronic SNS have been advocated as alternatives to the current methods of PN l i tes-
ting (11, I A, l(>). These approaches are unfortunately considerably more invasive than conventional
PNK. Coiled leads such as those investigated in this study might allow PNE testing to be improved in
Accuracy without recourse to more involved, invasive or costly alternatives.
Conclusions
Coiled lead designs appear to hold promise for improving the ability of PNE testing to identify cor-
rectly patients likely to benefit from sacral root neuromodulation. These novel leads can be effective
in applying SNS via the sacral loramina with reduced likelihood of subsequent loss of responsiveness
to stimulation resulting from lead migration. One of the two novel leads evaluated in the present study
could also be consistently removed without difficulty. This new lead merits further investigation in
human subjects, i
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BUTTOCK PLACEMENT OF THE IMPLANTABLE PULSE GENERATOR:
A NEW TECHNIQUE FOR SACRAL NERVE STIMULATION
Introduction Sacral ncuromodulation is an established and FDA approved therapy in patients with
urgcncy-lrequency, urge incontinence and urinary retention, in whom conservative treatment has fail-
ed ( I - I2 ) . In this therapy, the sacral nerve is stimulated by means of an implantable pulse generator
(IPO).
In I lie standard operation procedure, the Quad-lead (which is a wire with four electrodes) is placed
in the sacral foramen and connected to the IPG by means of an extension cable. The IPG is placed in
a subcutaneous pocket in the abdominal area. During this operation, the patient has to be turned from
a prone to a lateral decubitus position, reprepared and redraped. Three incisions have to be made.
First an incision at the level of the sacrum to implant the lead. A second incision in the (lank to con-
nect the lead to the extension cable, which has to be re-opened after turning the patient. A third inci-
sion is made in a skin crease in the lower quadrant of the abdomen to create a pocket that is large
enough to accommodate the stimulator. This pocket is created above the fascia of the external oblique
muscle, using this fascia as an anchor lor the sutures fixing the stimulator (13, H ) .
This operation procedure entails a long operation time ol approximately two-and-a-half hours. With
the 1 PCI in ihr abdominal wall, some patients complain of displacement or pain at the IPG site post-
opcralively. In addition, some patients complain about the disturbing magnetic fields at certain shop
counters. The IPG is sometimes turned off, because the abdominal region is in close proximity to this
Held. Bv modifying the technique of placement of the IPG from the abdominal to the buttock region,
the disadvantages above are overcome. This technique was first performed by A. Das, Albany
Medical Centre USA. in 13 patients and turned out to be a safe technique for sacral neuromodulation.
This article describes the technique of placement and compares the results of abdominal versus but-
tock placement ol the IPG with the published literature.
Material and methods We retrospectively reviewed 39 patients undergoing, between August 1999
and «Inly 2000, a bullock implant of the IPG for sacral nerve modulation. Birth-date, indication for
implantation, date of implantation, direct postoperative complications, late complications, current sta-
tus and the patients' satisfaction with their IPG's were obtained during postoperative consultation by
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their urologist. All patients were implanted using the same technique. The implantation is performed
under general anaesthesia, in different hospitals (see acknowledgements) by the same surgical team.
After administration of prophylactic intravenous antibiotics, the patient is positioned in a prone decu-
bitus position, with 30 degrees anteflexion of the hips and 30 degrees Ilexion ol the knees. The lower
back, tlanks, buttocks are prepared and draped sterile, using a transparent vertical sheet (Molnlyckv
model 826020-21). Both feet and the perineum are exposed under this transparent drape in order to
observe the typical motor reactions. The lead (Medtronic quadripolar lead, model 3080) is placed in
the selected sacral foramen according to the standard procedure ( I 3 .H ) . Once the lead is fixed, a
transverse incision is made over the lateral-superior quadrant ol the buttock approximately A-10 cm
caudal to the iliac crest, large enough to accommodate the I!'(1 (Medtronic quadripolar IP(>, model
3023). The pocket is created by means of blunt dissection in the subcutaneous fat, below Camper«»
fascia. The size of the pocket is sufficient if 3 digits can be inserted. The lead is then tunneled mibcu-
taneously, between the sacral wound and the buttock wound using a special tunneling device. The lead
is connected to the lead extension of 10 cm (Medtronic, model 3095) mechanically and isolated. The
lead-extension is connected to the I PC mechanically. The surplus wire is coiled up behind the IPCI ,
which is then inserted into the subcutaneous pocket, with the inscripted part lacing the skin, in order
to allow telemetric programming. In buttock placement of the IPG only a short lead extension ol 10
• Urge-incontinence F"g- ' / '"" '«' ' i / ///fV<v///*i//.</'/•.i,/,vv;/
• Urgency-frequency '"''•''<' . / / /
Uninary retention
# Fecal incontinence
# Pelvic pain
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cm is used to reduce coiling of the wire behind the I PC. The IPG is connected to the extension cable
and placed into this pocket. The wound is flushed with antibiotics and carefully closed in two layers.
Results The average age of the patients was 51 years (range 33-72 years). Of these 39 patients. 22
wert- diagnosed with urge-incontinence, 6 with urgency-frequency syndrome, 9 patients with urinary
retention, I with pelvic-pain syndrome and I with faecal incontinence (fig. 1). in two ol these patients,
the IPG wan repositioned from the abdominal position to the buttock on account of abdominal dis-
comfort. The average follow-up time was 5.3 months (range 1-10 months). Operation time for the
implantation of the ncuromodulalion system with the IPG in the buttock was approximately 1-1.5
hours. No repositioning of the patient is required during surgery using the buttock implant technique
with respect to the IPG. Only two instead of three incisions have to be made, i.e. an incision in the
flunk i» not needed anymore. Merely a short subcutaneous tunnel is required to connect the lead at
the level of (he sacrum to the IPG at the level of the buttock.
During follow-up, ranging from I to 10 months, 4 patients had some pain/discomfort at the level of
tin- IPG implant site (I 1%), which was treated with simple oral analgesics (e.g. paracetamol) post-
operalively, if necessary. In none of them a re-operation was required to replace the IPG. After 6
months, follow-up 3 out of 18 patients (17%) had some pain/discomfort at the level of the IPG, which
needed no further treatment. This accounts for 8% of the total group of 38 patients. Two patients were
seen with a postoperative hemutoma (5%). One hematoma was located at the level of the IPG in the
buttock, tIn* other hematoma was scon at the abdominal region after removing the IPG at that level
and placing it at the level of tin- hut lock. These hematomas were treated conservatively and resolved
completely. In this study, no infections were seen. No problems were noted by the patient or the phy-
sician concerning the programming of the IPG. The two patients with a previous abdominal placement
of the IPG. reported no complaints and preferred the buttock position.
DiSCUSSIOn Sacral nerve stimulation is an exciting method for urologists as it offers treatment oppor-
tunities lor patients for whom no treatment was available until now. This therapy is especially useful
in patients with urge incontinence which is resistant to medication and idiopathic voiding dysfunction
(15). As has been described by Siegel (13). the implantation technique for this therapy had some dis-
advantages that were mentioned previously. Weil et al. showed that the main adverse event of sacral
nerve stimulation is pain at the implantation site of the IPG in 29% of patients. This accounts for 42%
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of the total of adverse events noted in that study (16). Shaker and Hassouna noted 10% and 12% pain
at the IPG site, which resulted in re-implantation of the IPG (6, 9). Elabaddy et al. showed pain in I
patient out of 17 (6%), which resulted in removal of the IPG (7). Dijkema et al. presented 5 patients
out of 19 (26%) with pain at the IPG site. Bosch and Groen showed that 1 out of 18 patients (6%)
experienced pain at the IPG site, which resulted in re-implantation of the IPG (8). Weil et. al. showed
in 4 patients out of 36 (12%) with pain at the IPG site, resulting in re-operation (15). Schmidt et al.
presented in 83 of 157 patients adverse events, 23 of the patients (15,9 %) reported pain at the implan-
tation site of the IPG. This resulted in 22 surgeries to reposition the IPG (17).
When these data were combined (fig. 2), a mean of 17% of patients with pain at their abdominal IPG
site was found, which led to a considerably high re-operation rate. In this study, after implantation of
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the IPG in the buttock, 1 1% of patients complained about pain at the IPG site. None of these patients
needed to be re-operated because of pain at the IPG site over time. The pain at the IPG site seemed
to decrease, as at 6 months only 8% of the patients noted some pain/discomfort at the level of the IPG.
Also in these cases no further treatment was needed. One patient complained about a numb feeling
around the location of the I PC» (.3"/») that was not recovered after six months.
The operation lime of the implantation of the ncuromodulation system with the IPG in the abdominal
region i .i|>|>roximately 2.5 hours. Implantation of the neuromodulation system with the IPG in the
buttock takes approximately 1-1.5 hours. This reduction in operation time from approximately 2.5
hours to 1-1.5 hours is mainly due to the fact that the patient does not have to be turned from a prone
to a lateral dccuhilus position. Only two incisions are needed in this technique in stead of three. The
incision in I he Hank, which needed to be closed two times (e.g. before turning the patient and after
surgery), itt not necessary. The patient does not have to be reprepared and redraped. In this techni-
c|iu\ a short subcutaneous tunnel is needed to conned the IPG to the lead, as compared to the abdo-
minal implantation. leaving out these factors also reduces the risk of infection. The buttock implantation
technique provides advantages to both the patient and to the urologist. Therefore, in our opinion this can
be considered an improvement for sacral nerve stimulation and the first choice implantation technique.
AknowledgementS We would like to thank prof. dr. H. Hedlund, Dept of Urology, University
Hospital, in Oslo, Norway: dr. l i . Schurch, Swiss paraplegic centre 'Paracare', Zurich, Switzerland;
dr. A. Garbeglio and dr. H. Ostardo, Dept ot Urology. Ospedale S. Maria degh Angeli Porderone; dr.
A. Molon and dr. M. Pastorello. Dept of Urology. Ospedale Sacro Cuore Don G. Calabria Verona: dr.
C. Ratio, Dept ol Surgery, Catholic University I^argo A. Gemelli, Rome. Italy; prof. dr. J . Nordling,
Dept of Urology. Herlev Hospital, Copenhagen, Denmark, Prof. dr. G. Jakse and dr. D. Rohrman,
Urologische Klinik der RW'Tl 1-Aachen, Germany.
Conclusion Buttock placement of the IPG in sacral nerve stimulation involves less pain at the IPG
implantation site, shorter operation time, two instead of three incisions and a shorter subcutaneous
tunnel. Patients seem to prefer the buttock position of the IPG. Applying this technique for sacral
nerve stimulation is advantageous for the patient and the urologist.
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SUMMARY AND CONCLUSIONS
Chronic lower urinary tract dysfunction such as motor urge incontinence, urgency frequency syndro-
,n , and bladder evacuation problem, i . a challenging therapeutic problem. Most pat.ents are m.t.aHy
treated conservatively with bladder retraining, pelvic floor exercises and biofeedback tra.mng. In the
majority of cases, this regimen is supplemented with anticholinergic drugs. These approaches b,l to
yield satisfactory outcomes in an estimated 40% of patients. In these refractory problems, a l te rna te
invasive interventions with variable success rates such as intravesical installations of Capsa.cn^blad-
der transection, «ransvesical phenol injection of «he pelvic plexus, augmentation cystoplasty. and even
urinary diversion have been advocated. However, the high rates of recurrent incont.nence as well as
significant complications limit the appeal of these procedures.
Neuromodulation i . a new minimal invasive approach based on stimulation of the sacral nerves that
aims at (.eating lower urinary tract dysfunction.
This thesis evaluates the place of neuromodulation in patients with the above mentioned types of lower
urinary trait dysfunction.
SUMMARY . . .
CAH-KR , gives a general introduction on the storage and evacuation problems of the lower unnary
tract and the aims of this thesis.
CHAPTKR , reviews the published literature on the anatomy and neurophysiology of the lower unnary
„• u . Alter a brief introduction on the anatomy of the lower urinary tract.
,, ; . a , , | . - „ „ „ ion of tin- bladder (storage and evacuation of urine ). the normal innerv.t.on of the
lower urinarv u - , and the influence of the peripheral and centra, nervous systems are presented.
c n x n , K , describes the pathophysiology of lower unnary tract dysfunction. The d.rterent C a s s a -
tions and pathophvsiologic entities of lower urinary tract dysfunction are described
CHARTKR < presents the history of the development of neurostimulation. The working mechanism of
neuromodulation. the technique of percutaneous nerve evaluation and the technique of permanent
implantation arc described.
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CHAPTER 5 gives the first clinical results oi a teasibilitv study un ncuromodulation of sacral nerves tor
incontinence and voiding dysfunction. 19 out of 23 patients with an implanted neuroprosthesis for
neuromodulation showed a more than 50% improvement and N out of 23 a more than % % impro-
vement ot their main symptoms after a median follow up of 12 months. In «he urge incontinent
patients, the number of leakage episodes decreased from 7.4 to 1.6 / day and the functional capacity
ot the bladder increased from 135 to 227 ml. Two of the three patients with retention voided without
residual urine. Complications were limited.
CHAPTKR 6 introduces a new implantation technique. The two-stage implant technique increased the
results ot neuromodulation. In 10 patients in whom the original percutaneous nerve evaluation had
tailed to improve the micturition diary parameters such as the amount of urine voided, the frequency
ot micturition, the number ol pads used, the volume of urine lost and ilu- urge ii> urin.iio wil l i more
than 50 %. 8 had a good to very good result (60 % - 90 % improvement) during the testing period .nul
were implanted with a permanent implant 5 to H days after the first stage.
CHAPTER 7 presents the long- term clinical results of sacral neuromodulation for chronic voiding dys-
function using unilateral sacral foramen electrodes. The aim of the study was to determine the long-
term clinical efficacy and complications of neuromodulation with a unilateral sacral foramen electro-
de in 36 patients with chronic voiding dysfunction, fol lowing a positive effect of a 3 to 4 day percu-
taneous nerve evaluation test, patients underwent open surgery. A permanent electrode was implan-
ted in 24 patients with urge incontinence, in 6 with urgency frequency syndrome, and in 6 with non-
obstructive urinary retention. After an average follow-up period of 37.8 months, 19 patients (52.8 %)
continued to benefit from the neuromodulation with significant improvement of symptoms and uro-
dynamic parameters. The median duration of the therapeutic effect for the total study population was
longer than 60 months. No significant difference in the median duration ol the therapeutic effect with
regard to sex, type of voiding disorder, or implant pulse generator was found. However, in patients
with previous psychological disorders the median duration of therapeutic effect was only 12 months
(p< 0.008). Complications were limited. In the group of patients in whom the therapeutic effect remai-
ned, 37 re-operations had to be performed. Although re-operations were needed to overcome techni-
cal problems, patients achieve lasting symptomatic improvement. Special attention is needed with
regard to patients with a previous history of psychological dysfunction and sexual abuse. The data
indicate that 82% of these patients showed poor results as compared with 28% of the patients without
a history of psychological disorders (P=0.002).
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CHAI'TKK 8 presents the results of a prospective randomized clinical trial of sacral root neuromodula-
tion in the treatment of refractory urinary urge incontinence. Forty-four patients with refractory urge
incontinence were randomized to undergo neuromodulation with an implantable impulse generator
(21) or to continue with their previous conservative management (23).
At 6 months, the control group was eligible for a crossover to implant. The mean number of leakage
episodes, leakage severity and pad usage in the implant group was significantly lowered by 88% (p<
0.0005), 24% (p<0.047) and 90% (p<0.0005), respectively, compared to the corresponding control
group mean valued. Improvements in leakage episodes and pad usage of >90% were needed in 75 and
85% ol the implant group, respectively, but in none of the control group. One-third of implanted
patients, but none ol the control patients, achieved > 50% improvement in leakage severity. Over half
of the implanted patients (56%) were completely dry compared with only 1 control patient (4%).
Implant patients, but no control patients, exhibited significant improvement with respect to two quali-
ty-ol-life measures. Neuromodulation resulted in increases of 220% (p<0.0005) and 39% (p<0.013),
respectively, in urodynumically assessed bladder volume at first contraction and maximum fil l. At 36
months, the actuarial rate of treatment failure was 32.4% (95%CI, 17.0-56.0%). Adverse events most
frequently involved were pain at implant site, although the incidence of serious complications was low.
We conclude that neuromodulation is markedly more effective than conservative management in alle-
viating symptoms of refractory urge incontinence. Quality of life and urodynamic function also impro-
ve. The ellects of neuromodulation are long lasting, and the associated morbidity is low.
CHAPTKR ') presents the evaluation of the ability of two novel coiled test stimulation lead designs to
reduce or eliminate undesired migration and concomitant loss or attenuation of responsiveness to
sacral nerve stimulation associated with standard percutaneous nerve evaluation leads is presented.
Coiled lead designs to offer a potentially promising alternative to standard leads for percutaneous
nerve evaluation, allowing a larger number of patients to be correctly identified as candidates for
sacral root neuromodulation. Particularly the coiled lead with the coil type tip merits further investi-
gation in human subjects.
CHAI'TKR 10 outlines buttock placement of the implantable pulse generator, a new technique for sacral
nerve stimulation is outlined. This new technique of implantation is performed under general anaest-
hesia. After administration of prophylactic intravenous antibiotics, with the patient in a prone decu-
bitus position, the lead is placed in the selected foramen through a sacral midline incision. The sti-
mulator is placed in a subcutaneous pocket in the lateral-superior quadrant of the buttock approxi-
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matelv 5-10 cm caudal to the iliac crest. 39 patients were implanted, 22 with urge incontinence, 6 with
urgency-Frequency syndrome. 9 with urinary retention. 1 with pelvic pain syndrome and 1 with faecal
incontinence. The average follow-up time was 5.3 months ( 1 - 1 0 months) . There \N.I* -I reduction in
operation time of 1 - 1.5 hours. Buttock placement of the implantable puls«- .••<-n<-r.ii..i m .u ral nerve
stimulation entails less pain at the implant site, shorter operation time, two instead ol tluce incision»
and a shorter subcutaneous tunnel. We conclude thai buttock placement is superior to standard posi-
tioning of the implantable pulse generator. It is advantageous for both the patient and the surgeon.
Conclusions The technique of neuromodulation as described in this thesis haw proved in In- a relia-
ble treatment for patients with severe voiding dysfunction. Complication IM i n < .md result« long las-
ting. With the new percutaneous flexible test lead more patients with lower urinary truct dysfunction
can be selected for neuromodulation. The two-stage implant technique can be of benefit for I hose
patients in whom the percutaneous test result does not justify definitive implantation of the implanta-
ble pulse generator. Buttock placement of the implantable pulse generator has proved lo be superior
over standard abdominal placement and is nowadays the technique o( choice.
We expect that neuromodulation will become a routine treatment procedure in the daily practice ol
the urologist, although it requires careful training. We hope that with further research in the field of
electrostimulation this treatment will become available for a larger group of patients not only with uri-
nary voiding dysfunction but also for patients with defaecation problems.
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SAMENVATTING EN CONCLUSIES
Chronische disfuncties vun de läge urinewegen, zoals motor-urge incontinentie. urgency-frequency
syndroom en blaasledigingsproblemen zijn uitdagende therapeutische problemen in de urologie. De
mci-Nlc pati#ntcn worden in cerate instantie conservatief behandeld door middel van blaastraining,
bokkenbodemoeleningcn en biofeedback. In de meerderheid van de gevallen wordt aan dit regime een
medicamenteu/.e behandcling met anticholincrgica toegevoegd. Bij ongeveer 40% van de patienten
leveren doze behandelingen niet het gewenste resultaat op. Aansluitend volgen dan alternatieve. meer
ingrijpendc procedure», die wisselend succes opleveren.
Vonrbeeldcn hiervan zijn intravesicale instilluties met Capsaicine, blaastransectie, transvesicale phe-
nol-injt'i'tivR van de pelvine plexus, augmentatie- ileocystoplastiek, zelfs urinedeviaties volgens
Brickcr en continente urinedeviaties. AI deze behandelingen leiden tot een hoog risico op recidief van
de incontinentie. Daarnaast leveren zij veel complicates op.
Neuromodulatic is een nieuwe behandelingstechniek waarbij door middel van electrostimulatie van de
sacrale zenuwen disfuncties van de läge urinewegen behandeld worden.
In doze studie wordt de plants van neuromodulatie bij de behandeling van bovengenoemde disfunc-
ties van de läge urinewegen ge'i'valueerd.
In llooi-'DSTUK I wordt een algemene inleiding gegeven over de evacuatie en opslagproblemen van de
läge urinewegen en worden de doelstellingen van dit proetschritt uiteengezet.
In HOOI'DSTUK i wordt een overzicht gegeven van de gepubliceerde literatuur over de anatomie en
neurorysiologie van de läge urinewegen. Na een kort overzicht van de dubbele functie, te weten het
opslaan on evacueren van urine, wordt de normale zenuwvoorziening van de läge urinewegen en de
invlood van het perilere en centrale zenuwstelsel hierop besproken.
In HOOI'OSTUK 3 wordt de pathofvsiologie van mictiestoornissen geevalueerd. De verschillende clas-
siFicaties en pathologische entiteiten van de disluncties van de läge urinewegen worden beschreven.
In HOOKDSTUK -( wordt de geschiedenes van de ontwikkeling van neurostimulatie in de urologie gepre-
senteerd. Het werkingsmechanisme van de neuromodulatie, de techniek van percutane zenuwstimu-
latie on do mothodo van do implantatie van ilo sacrale zenuwstimulator worden beschreven.
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In HOOmSTL'K 5 worden de eerste klinische resultaten van een haalbaurheidsstudie naar hot ofleel van
neuromodulatie via sacrale zenuwstimulatie bij patienten met dislunctie van dc luge »ninewegen
gepresenteerd. 19 van de 23 patienten bij wie een neuromodulator geYmplanteerd werd. hadden MUHT
dan 50% en 14 van de 23 meer dan 90% verbetering van hun Symptomatologie na ecu medianc lollow-
up van 12 maanden. In de urge-incontinentie-groep daalde het aantal lokk.i;;<x van 7.4 naar 1.6 per
dag en nam de iunctionele capaciteit van de blaas toe van 135 naar 227 cc. 2 van de 3 paticntt*n met
urineretentie ledigden hun blaas zonder noemenswaardig rosidu. Kr trad slechts «-n hcpcrkl a.mial
complicaties op.
In HOOKDSTl'Kb wordt een nieuwe techniek van implantatie gointroduieeid. De implant.itu'lci hnick
in 2 Fasen verbeten de resultaten van neuromodulatie significant. Bij 8 van de 10 patii'ntcn waarbij de
percutane zenuwstimulatie gefaald had om een verbelering van de mictieparametcrti, y.oalt» mictiehoe-
veelheid, mictiefrequentie, het aantal verbanden, de hoeveelheid urineverlics on de male van drang
van meer dan 50% te geven, bleek gedurende de eerste fase van de operatie een goed tot zeer goed
resultaat (60-90% verbetering) op te treden. Bij hen werd vervolgens overgegaan tol definitieve
implantatie 5 tot 14 dagen na de eerste fase.
In HOOFDSTUK 7 worden de lange-termijnresultaten van sacrale neuromodulatie voor chronische mic-
tiestoornissen door middel van unilaterale, sacrale (oramenstimulatie gepresenteerd. I let doel van de
Studie was om de lange termijn effectiviteit te bepalen en de complicaties bij 36 patienten. Bij een posi-
tiet effect na een percutane zenuw stimulatie test ondergingen deze patienten een delinitieve implan-
tatie. Een permanente elektrode werd geimplanteerd bij 24 patienten met urge-incontinentie, bij 6 met
urgency-frequency syndroom en bij 6 met een niet-obstructieve urineretentie. Na een gemiddelde fol-
low-up van 37,8 maanden hadden 19 patienten (52,8%) continu voordeel van de neuromodulatie met
significante verbetering van de Symptomen en urodynamische parameters. De mediale duur van het
therapeutische effect voor de totale studiepopulatie was langer dan 60 maanden. Geen significant ver-
schil in de mediale duur van het therapeutische effect betreffende sekse, type van mictieprobleem ol
geYmplanteerde puls-generator werd gevonden. Bij patienten met vroegere psychologische problemen
echter bleek de mediale duur van het therapeutisch effect slechts 12 maanden (p = 0,008) te zijn. De
complicaties waren mild. In de groep van patienten bij wie het therapeutisch effect goed bleel, wer-
den echter wel 37 re-operaties uitgevoerd. Wi) concluderen dat patienten een langdurige symptomati-
sche verbetering kunnen verkrijgen door middel van neuromodulatie, alhoewel technische problemen
door middel van reoperaties opgelost moesten worden. Speciale aandacht is vereist bij patienten met
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een vroegere geschiedenis van psychologische problematiek of seksueel misbruik. 82% van deze
patienten vcrtoonden een siecht resultaat in vergelijking met 28% van de patienten zonder deze voor-
£ • • ' I I I . - . I . - n i s ( p - 0 . 0 0 2 ) . : •• : • • •
in HOOKDSTUK 8 worden de nsultaten van een prospectieve, gerandomiseerde, klinische Studie naar
het effect van sacrale zenuwneuromodulalic bij de behandeling van hardnekkige onbehandelbare
urine urge-incontinentie gepreaenteerd. 44 Patienten met onbehandelbare urge-incontinentie werden
gerandomiseerd nm neuromodulatie met een implanteerbare puls-generator ( 21) te ondergaan ot gin-
gen door met een oorspronkelijke conservatieve behandeling (23). Na 6 maanden werd de controle-
grocp geYrnplanteerd. I let gemiddelde aantal lekkage-episodes, de ernst van de lekkage en het aantal
verbanden dat werd gebruikt in de implantgroep werd significant lager, resp. bij 88% (p < 0.0005),
24% (p < 0,0047) en 90% (p < 0,005), dan de gemiddelde waarden ten opzichte van de controlegroep.
Vermindering van het aantal Ickkage-episodes en verbandgebruik van meer dan 90% werden bereikt
bij 75 en 86% van de geYmplanteerde groep en bij geen van de patienten in de controlegroep. Ken
derde van de geYmplanteerde patienten en geen van de controlepatienten bereikten meer dan 50% ver-
betering in de ernst van de lekkage. Meer dan de hellt van de geYmplanteerde patienten (56%) werd
volledig droog in vergelijking tot I patient in de controlegroep (4%). De geYmplanteerde patienten en
geen van de conlrolepatienten ervoeren een significante verbetering bij 2 kwaliteit- van-leven-maten.
Neuromodulatie rcsulteerde in een verbetering van 220% (p < 0,0005) en 39% (p < 0,013) respectie-
velijk van het urodvnamisch aangetoonde blaasvolume bij de eerste blaassamentrekking en maximaal
blaasvolume. Na 3b maanden was het leitelijke percentage van behandelingslalen 32,4% (95% CI,
17,0-n(i,0). De meest voorkomende bijwerking was pijn ter plaatse van de geYmplanteerde stimulator,
doch ernstige complicates deden zieh nauwelijks voor. Wij concluderen dat neuromodulatie duidelijk
effeetiever is dan conservatieve behandeling bij moeilijk tot onbehandelbare urge-incontinentie-
patie'nten. De kwaliteit van leven en de urodynamische parameters verbeterden door neuromodulatie.
Het effect van neurumodulatie is langdurig en de morbiditeit is laag.
In HOOKDSTUK 9 worden de ontwikkeling en de test van 2 nieuwe gespiraliseerde, flexibele testelek-
trodes geSvalueerd. In het verleden bleek dat met de standaard testelektrode er vaak migratie optrad,
waardoor de respons op de sacrale stimulatie verloren ging. De gespiraliseerde elektrodes hebben een
betcre fixatie dan de standaard testelektrode. De gespiraliseerde elektrode met spiraaltip leverde de
beste resultaten in een dierexperimentele Studie op.
In HOOKDSTUK 10 wordt een nieuwe techniek van implantatie van de puls-generator ter plaatse van de
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musculus gluteus geYntroduceerd en gee'valueerd. Deze techniek wordt onder algehele anesthesie uit-
gevoerd. Na toediening van profylactische intraveneuze antibiolica mot do patient in buikligging
wordt de elektrode in het geselecteerde foramen gefixeerd via cen mcdiane sacrale incisie. l)e stimu-
lator wordt in een subcutane pocket in het laterale bovenkwadrant boven de MUHCUIUS Gluteua
Maximus op 5 tot 10 cm. caudaal van de Crista Iliaca Superior geplaatst. 3*) patiitaton werden geVm-
planteerd waarvan 22 met urge incontinontio. (> met urgency Iroijuency svndrooin, *) met urinereten-
tie. 1 met bekkenbodempijn en 1 met locale incontinentie. Do gemiddeldc follow-up was ft.3 maatulon
( 1 - 1 0 maanden). Er was een vermindering van de operatietijd van I - 1.6 uur. Wij concludeerden dat
gluteale plaatsing van de neurostimulator een betere techniek is dan de oorspronkolijko standaard-
operatie ( abdominale positie). Gluteale plaatsing van de stimulator veroorzaakl minder pijn ter plaat-
se van de implantatieplek, leidt tot kortere operatietijd als gevolg van een kortere submuceu/o iimm-l
die gemaakt moet worden en het feit dat er slechts 2 in plaats van 3 incisiea moeten worden geinaakt.
De techniek heeh zowel voor de patient als voor dc chirurg grote voordelen.
Conclusies De techniek van neuromodulatie zoals beschreven in dit proefschrift heeft bewezen een
betrouwbare behandelingsmogelijkheid te zijn voor patienten met ernstige mictiestoornissen. De com-
plicaties zijn beperkt. De resultaten op lange termijn zijn goed. Met de nieuwe ilexibele testelektrode
kunnen meer patienten geselecteerd worden voor neuromodulatie. Bij patienten waarbij de percutane
test geen betrouwbaar resultaat oplevert, kan de 2- fasen-operatietechniek alsnog een oplossing zijn
om toch nog over te gaan tot definitieve implantatie van de neuromodulator. De Gluteale implanta-
tietechniek blijkt betere resultaten te hebben dan de standaard abdominale implantatietechniek en is
tegenwoordig de operatietechniek van eerste keuze. Wij verwachten dat neuromodulatie in de naaste
toekomst een routinebehandehng zal worden in de dagelijkse urologische praktijk. Wij hopen dat door
verdere research op het gebied van elektrostimulatie deze behandelingsmogelijkheid in de toekomst
bij grotere groepen patienten toegepast kan worden, en dat niet alleen voor patiönten met mictie-
stoornissen doch ook bij patienten met delecatieproblematiek.
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